

expression was not detected. COX-2 and PGE₂ synthesis was detected in endothelial cells of squamous cell carcinoma, and columnar and glandular epithelium of adenocarcinoma, but not in normal cervical tissues. In vitro culture of cervical cancer biopsies demonstrated that the induction of cAMP by PGE₂ was significantly higher in cervical carcinoma tissue than in normal cervix. Thus, PGE₂ potentially regulates neoplastic cellular functions in cervical carcinoma in an autocrine/paracrine manner via EP4 (Sales et al., 2001). The same group also demonstrated COX-1-induced expressions of EP1–4 as well as enhanced cAMP production in response to PGE₂ and PGE₂-induced EP4 expression in HeLa (cervical adenocarcinoma) cells (Sales et al., 2002). Further study is required to clarify the roles of PGE₂-EP4 signaling in cervical cancer.

4. Breast Cancer. Different groups similarly demonstrated expression of EP4 in MCF-7, a breast cancer cell line (Renò et al., 2004; Pan et al., 2008), and in murine breast cancer cell lines (Ma et al., 2010). EP4 expression was detected in human breast cancer specimens, and it was positively correlated with expression of COX-2 (Pan et al., 2008). Immunohistochemical analysis in COX-2-induced breast tumors in mice detected EP4 expression in stromal cells, adipocytes, and hematopoietic cells but no expression in ductal and alveolar epithelial cells, whereas EP2 was expressed in ductal and alveolar epithelial cells, suggesting the role of EP4 in mesenchymal cells (Chang et al., 2004).

EP4 regulates tumor growth and metastasis of breast cancer cells. EP4 antagonists inhibited proliferation of breast cancer cells (Ma et al., 2006). Stimulation of EP4 resulted in increased cell proliferation and invasion of inflammatory breast cancer, an aggressive form of breast cancer, but not of noninflammatory breast cancer. In contrast, EP2 had no such effect on either of the two cell lines. It has also been demonstrated that knockdown of EP4 abolished EP4-mediated cellular proliferation and invasion (Robertson et al., 2008). An attempt to inhibit EP4-mediated breast cancer progression was successful, at least in animal studies. Continuous oral administration of the EP4 receptor antagonist ONO-AE3-208 decreased tumor growth, lymphangiogenesis, angiogenesis, and metastasis to the lymph nodes and the lungs of xenografted human breast cancer cells in mice (Xin et al., 2012). In addition, antagonism of EP4 receptor with either AH23848 or ONO-AE3-208 reduced metastasis of murine breast cancer cells (Ma et al., 2006). Aside from synthetic compounds, Frondoside A, a triterpenoid glycoside derived from the sea cucumber *Cucumaria frondosa*, was found to antagonize EP4 and to inhibit cAMP production and ERK activation. Frondoside A also inhibited spontaneous tumor metastasis to the lungs in vivo, and may be used as an

EP4 antagonist to prevent metastasis in breast cancer (Ma et al., 2012). As described earlier, EP4 is expressed in mesenchymal cells rather than ductal and alveolar epithelial cells (Chang et al., 2004). In that study, it was demonstrated that a COX-2 inhibitor suppressed angiogenesis in xenografted tumors, suggesting a potential role of EP4 in angiogenesis, although a selective inhibitor for EP4 was not tested. An interesting feature of PGE₂ in breast cancer is its involvement in production of estrogen, a key stimulator for breast cancer progression. Both PGE₂ and agonists for EP4 can enhance CYP19 transcription and thereby induce the expression of aromatase, which is critical for the local synthesis of estrogen, through the cAMP/PKA/CREB pathway. PGE₂ also suppressed expression of breast cancer susceptibility gene 1, a major tumor suppressor gene in breast cancer (Subbaramaiah et al., 2008).

5. Prostate Cancer. EP4 expression was detected in human prostate cancer cell lines (Chen and Hughes-Fulford, 2000; Wang and Klein, 2007; Swami et al., 2009) and primary cancer-derived cell culture as well as normal prostate cell culture (Swami et al., 2009). In castration-resistant prostate cancer, an advanced form of androgen-insensitive prostate cancer, expression of EP4 was upregulated during progression of castration resistance (Terada et al., 2010).

PGE₂ activates cell migration of prostate cancer cells via EP4. These functions were regulated at least in part by transactivation of EGFR and β 3 integrin in prostate cancer (Jain et al., 2008). When EP4 was overexpressed in LNCaP human prostate cancer cells, progression of tumors occurred through androgen receptor activation. In castration-resistant prostate cancer cells, the EP4 receptor antagonist ONO-AE3-208 decreased intracellular cAMP levels in vitro and tumor growth in vivo (Terada et al., 2010). Expression of S100A8, a calcium-binding protein which is highly expressed in prostate cancer, was enhanced by PGE₂ and inhibited by both EP4-specific inhibitors. Increased promoter activity of S100A8 via EP4 was potentially mediated by PKA (Miao et al., 2012).

6. Ovarian Cancer. In ovarian cancer cell lines, expression of EP4 was demonstrated in relation to endothelin signaling. Spinella et al. (2004a,b) reported that endothelin-1 (ET-1) induced COX-1 and COX-2 expression through endothelin receptor. Both enzymes contributed to production of PGE₂ in human ovarian carcinoma cell lines (Spinella et al., 2004b). Subsequently, they demonstrated that ET-1 increases expression of EP4, and that PGE₂ induced by ET-1 activates cell invasion and production of vascular endothelial growth factor via EP4 (Spinella et al., 2004a).

7. Other Cancers. The role of EP4 has been reported in other cancer types, such as gallbladder carcinoma, T-cell leukemia cells, renal cancer, and upper urinary carcinoma. Expression of EP4 has been detected in

human gallbladder carcinoma specimens. An EP4 receptor agonist and PGE₂ increased colony formation of gallbladder cancer cells probably via increased expression of c-Fos (Asano et al., 2002). George et al. (2007) demonstrated that PGE₂ decreased camptothecin-induced apoptosis in Jurkat human T-cell leukemia cells. This effect occurred through the EP4/PI3K/Akt pathway, but not through the EP4/PKA pathway (George et al., 2007). PGE₂ increased the invasion of RCC7, a human renal cancer cell line that expresses abundant EP4. Inhibiting EP4 with its antagonists AH23848 and GW627368 or shRNA-mediated EP4 disruption similarly inhibited RCC cell invasion. Rap1 was identified as a potential molecule involved in this process; its activation was blocked by AH23848 (Wu et al.). Another report showed that EP4 involvement in invasion of renal cell carcinoma cells via the Akt/Ral GTPase-activating protein complex 2/RalA small GTPase (Li et al., 2013). Finally, EP4 is a potential cancer biomarker. An immunohistochemical study suggested that analyzing the coexpression of COX-2 and EP4 was useful for evaluating progression of nonmetastatic transitional cell carcinoma of the upper urinary tract (Miyata et al., 2005).

C. Immune System

1. Monocytes/Macrophages/Dendritic Cells.

a. Expression. Early studies demonstrated that EP4 mRNA was abundant in human peripheral blood leukocytes (An et al., 1993; Mori et al., 1996) as well as in the spleens of humans (An et al., 1993), mice (Honda et al., 1993), and rats (Sando et al., 1994). Thus, the EP4 receptor may play an important role in leukocytes and macrophages (Woodward et al., 2011). More recently, abundant expression of EP4 has also been demonstrated in mononuclear cells and macrophages, specifically in mouse macrophages (Ikegami et al., 2001; Akaogi et al., 2004; Pavlovic et al., 2006), the mouse macrophage cell line J774.1 (Katsuyama et al., 1998a), the mouse macrophage-like cell line RAW 264.7 (Tajima et al., 2008; Khan et al., 2012), and human macrophages (Bayston et al., 2003; Iwasaki et al., 2003; Kubo et al., 2004; Cipollone et al., 2005; Wu et al., 2005). Takayama et al. (2002) have demonstrated that EP4 is a primary receptor expressed in macrophages, and therefore suggested that PGE₂ mediates the inhibition of MCP-1 and macrophage inflammatory protein-1 α (MIP-1 α).

In the past decade, emerging evidence has shown that chronic inflammation may increase EP4 expression. An example is the development of atherosclerosis, in which not only T cells but also mononuclear cells and macrophages play a role (Ross, 1999). Cipollone et al. (2005) characterized EP4 expression in plaques from symptomatic and asymptomatic patients undergoing carotid endarterectomy. They found a correlation with the extent of inflammatory infiltration: EP4 was

present in asymptomatic patients but was increased in symptomatic patients, leading to an enhanced inflammatory reaction in response to atherosclerotic plaques (Cipollone et al., 2005). This pattern was most obvious in EP4; the expression of EP2 was very low, whereas EP1 and EP3 were not detectable.

b. Function. EP4 signaling regulates a variety of cytokines and chemokines in macrophages, and plays roles in their anti- and proinflammatory activity (Woodward et al., 2011; Tang et al., 2012) (Table 3). In macrophages, most studies suggest that EP4 is anti-inflammatory because it is through EP4 that PGE₂ suppresses the production of cytokines and chemokines, such as TNF- α , IL-12, and MCP-1. Nevertheless, accumulating evidence shows that EP4 receptor signaling also promotes proinflammatory cytokine IL-6 in macrophages

i. Tumor necrosis factor- α . PGE₂ acts as a major feedback inhibitor in TNF- α production from macrophages (Zhong et al., 1995). LPS treatment of macrophages can induce TNF- α production and results in a concomitant increase in PGE₂ production. Released PGE₂ then acts on the macrophages as an inhibitor of TNF- α production in an autocrine manner (Zhong et al., 1995). Through experiments with the genetic deletion of EP4 in macrophages, Nataraj et al. (2001) demonstrated that suppression of TNF- α production was mediated by EP4. In vitro pharmacological studies also demonstrated that EP4 inhibited TNF- α production in monocytes/macrophages in humans (Meja et al., 1997; Ratcliffe et al., 2007), mice (Katsuyama et al., 1998a; Yamane et al., 2000; Ikegami et al., 2001; Akaogi et al., 2004; Nakatani et al., 2004), and rats (Treffkorn et al., 2004; Aronoff et al., 2008).

Furthermore, TNF- α gene expression is negatively regulated by cyclic AMP-elevating agents, including β -adrenoreceptor agonist, G_s α stimulator cholera toxin, cAMP analogs, and PDE IV inhibitor (Severn et al., 1992; Prabhakar et al., 1994; Seldon et al., 1995; Aronoff et al., 2008). Some studies have used analogs of cAMP to address the relative contributions of the cAMP effectors PKA and Epac. LPS-induced TNF- α production was only inhibited through the PKA pathway in monocytes and macrophages, although Epac was present in these cells (Aronoff et al., 2005; Bryn et al., 2006). Wall et al. (2009) demonstrated that suppression of the expression of the gene encoding TNF- α involved the targeting of type II PKA by AKAP95 to an NF- κ B complex that includes p105. Similarly, the expression of the gene encoding MIP-1 α was also inhibited by the targeting of type II PKA by AKAP to an NF- κ B complex (Wall et al., 2009). This body of evidence suggests that, in general, cAMP-PKA signaling suppresses TNF- α production. Most studies have demonstrated that not only EP4 but also EP2 signaling suppresses TNF- α production (Meja et al., 1997; Katsuyama et al., 1998a; Yamane et al., 2000; Ikegami et al., 2001; Nataraj et al., 2001; Akaogi et al.,

TABLE 3
Reported roles of EP4-mediated signaling pathways in the immune system

Tissues/Cells	Reported Functions	Proposed Effector Pathway(s)	References
Macrophages	Inhibition of TNF- α production	EP4 receptor-associated protein	Takayama et al., 2006
Monocytes	Inhibition of TNF- α production	N.D.	Meja et al., 1997; Katsuyama et al., 1998a; Yamane et al., 2000; Ikegami et al., 2001; Nataraj et al., 2001; Akaogi et al., 2004; Nakatani et al., 2004; Treffkorn et al., 2004; Ratcliffe et al., 2007; Aronoff et al., 2008
	Inhibition of MCP-1 production	EP4 receptor-associated protein	Takayama et al., 2006
	Inhibition of MCP-1 production	N.D.	Hishikari et al., 2009; Tang et al., 2011a; Tang et al., 2011b
	IL-6 production	cAMP; PKA; PKC; p38 MAPK; NF- κ B	Chen et al., 2006
	IL-6 production	PKC	Ma and Quirion, 2005
	IL-6 production	N.D.	Bayston et al., 2003; Akaogi et al., 2004; Treffkorn et al., 2004
	MMP-9 production	ERK1/2	Steenport et al., 2009
	MMP-9 production	N.D.	Cipollone et al., 2005; Pavlovic et al., 2006
	Inhibition of IL-12 production	cAMP	Iwasaki et al., 2003
	Inhibition of IL-12 production	N.D.	Ikegami et al., 2001; Nataraj et al., 2001; Kuroda and Yamashita, 2003
Dendritic cells	Inhibition of IL-12p70, IL-6, and IL-10 production	cAMP	Kubo et al., 2004
	IL-23 production	cAMP; Epac	Yao et al., 2009; Sakata et al., 2010b
	Migration	cAMP; PKA; p38 MAPK	Scandella et al., 2002; Cote et al., 2009
	Migration	cAMP	Luft et al., 2002
	Migration	N.D.	Legler et al., 2006
Langerhans cells	Migration	N.D.	Kabashima et al., 2003
T cells	Inhibition of IL-12, IFN- γ , MIP-1 α production	N.D.	Ogawa et al., 2009
	Th17 expansion	cAMP; PKA	Yao et al., 2009; Sakata et al., 2010a,b
	Th17 expansion	N.D.	Gagliardi et al., 2010
	Th1 differentiation	PI3K	Yao et al., 2009
Eosinophils	Inhibition of migration	PI3K; PKC	Luschnig-Schratl et al., 2011
	Inhibition of migration	N.D.	Konya et al., 2011
Neutrophils	Inhibition of TNF- α production; IL-6 production	N.D.	Yamane et al., 2000
	Inhibition of aggregation	N.D.	Wise, 1998

N.D., not determined.

2004; Treffkorn et al., 2004; Ratcliffe et al., 2007; Aronoff et al., 2008). These data also support the concept that cyclic AMP-PKA is involved in PGE₂-mediated suppression of TNF- α production, because both EP4 and EP2 are positively coupled to ACs and increase intracellular cAMP production.

ii. *Monocyte chemoattractant protein-1*. MCP-1 is known as a chemotactic factor and plays essential roles in the recruitment of inflammatory cells into tissues. Takayama et al. (2002) suggested that PGE₂ suppressed the production of MCP-1 in LPS-activated human macrophages via EP4. The structure of EP4 itself was associated with suppression of MCP-1 production in human monocyte-derived macrophages (Takayama et al., 2006). Lack of EP4 in bone marrow-derived cells accelerated local inflammation in atherosclerotic and aneurysm lesions, leading to increased aneurysm formation (Tang et al., 2011a). Similarly, when EP4 was activated, it decreased MCP-1 production, as in ischemia/reperfusion injury, as well as inflammatory cell infiltration in mouse ventricles (Hishikari et al., 2009). Given that targeted disruption

of the MCP-1 gene or its receptor C-C chemokine receptor type 2 significantly decreased atherogenesis in mice (Boring et al., 1998; Gu et al., 1998), inhibition of MCP-1 by EP4 may play a beneficial role, especially in cardiovascular diseases. It has been demonstrated that MCP-1 expression was suppressed via the cAMP-PKA pathway in multiple cell types (Iwamoto et al., 2003; Wuyts et al., 2003), including mononuclear cells (Yang et al., 2012). Thus, cAMP-PKA signaling may be a potential downstream signaling pathway for the EP4-mediated inhibition of MCP-1 production.

iii. *Interleukin-6*. IL-6 is a multifunctional cytokine that plays a central role in both innate and acquired immune responses. IL-6 is the predominant mediator of the acute phase response, an innate immune mechanism triggered by infection and inflammation (Graeve et al., 1993). PGE₂ has been shown to increase IL-6 production in peritoneal macrophages in vitro (Williams and Shacter, 1997). Both in vitro and in vivo studies have suggested that EP4 is a potent stimulant of IL-6 production. PGE₂-induced IL-6 production via EP4 has been demonstrated in mouse and rat

macrophages (Akaogi et al., 2004; Treffkorn et al., 2004; Ma and Quirion, 2005; Chen et al., 2006) and in various cell types, including neutrophils (Yamane et al., 2000), smooth muscle cells (Yokoyama et al., 2012), and fibroblasts (Inoue et al., 2002). PGE₂ also increased IL-6 production via EP4 in macrophages in human aortic aneurysms (Bayston et al., 2003). Intracellular signaling events involving p38 MAPK and NF- κ B as well as PKA and protein kinase C (PKC) are responsible for IL-6 induction by EP4 stimulation (Chen et al., 2006). Ma and Quirion (2005) also demonstrated the involvement of PKC signaling in EP4-induced IL-6 production in macrophages in a rat model of nerve injury.

iv. Matrix metalloproteinase-9. Macrophages produce MMP-9, which plays a principal role in the degradation of extracellular matrix components. It also modifies the activities of cytokines and chemokines, growth factors, and proteinase inhibitors (Parks et al., 2004). MMP-9 expression is low or absent in most normal tissues, but is markedly upregulated during chronic inflammation and cancer (Parks et al., 2004). MMP-9 expression was markedly reduced in macrophages isolated from COX-2-deficient mice and in wild-type macrophages treated with COX-2 inhibitors (Khan et al., 2004). Consistent with these results, pharmacological EP4 activation increased MMP-9 expression and activity in human monocytes and macrophages derived from atherosclerotic plaque (Cipollone et al., 2005). Similar results were shown in murine macrophages (Pavlovic et al., 2006; Steenport et al., 2009; Khan et al., 2012). Although studies using murine macrophages have suggested the involvement of cAMP and ERK1/2 in EP4-induced MMP-9 activation, further studies are needed to elucidate the precise signaling mechanisms involved in the process.

v. Interleukin-12. IL-12 plays critical roles in the induction of Th1 response by regulating the differentiation of Th0 to Th1 cells while suppressing Th2 cytokine development (Hsieh et al., 1993; Seder et al., 1993; Manetti et al., 1994). PGE₂ has been suggested to suppress LPS-induced IL-12 production by macrophages and dendritic cells (van der Pouw Kraan et al., 1995; Harizi et al., 2002). In keeping with these results, EP4 activation inhibited IL-12 production in human monocyte-derived dendritic cells (Kubo et al., 2004), human monocytes (Iwasaki et al., 2003), and mouse macrophages (Ikegami et al., 2001; Nataraj et al., 2001; Kuroda and Yamashita, 2003; Ogawa et al., 2009) *in vitro*. When T cells were stimulated with matured monocyte-derived dendritic cells induced by an EP4 agonist, they exhibited decreased Th1 cytokine interferon- γ (IFN- γ) production and increased Th2 cytokine IL-4 and IL-10 production (Kubo et al., 2004).

Cyclic AMP elevators, such as cholera toxin or forskolin, also mimicked the inhibition of IL-12 production by EP4 activation (Ikegami et al., 2001;

Iwasaki et al., 2003; Kubo et al., 2004; Schnurr et al., 2005; Kelschenbach et al., 2008; la Sala et al., 2009). Recent studies have demonstrated that negative regulation of NF- κ B and interferon regulatory factor 8 were mechanisms of cAMP-mediated downregulation of IL-12 (Kelschenbach et al., 2008; la Sala et al., 2009). In addition, Wall et al. (2009) demonstrated a direct positive effect of cAMP-PKA signaling on the expression of IL-10 through CREB. These findings suggest that PGE₂ induces Th2 polarization through EP4-cAMP signaling-mediated IL-12 suppression.

vi. Migration. Migration of dendritic cells from peripheral tissues to the T-cell areas of draining lymph nodes is crucial for the priming of T lymphocytes. PGE₂ is responsible for facilitating chemotaxis in human monocyte-derived dendritic cells (Luft et al., 2002; Legler et al., 2006); this activity has been ascribed to EP4 (Table 3). Indeed, in human blood monocytes or monocyte-derived dendritic cells, EP4 stimulation upregulated C-C chemokine receptor 7 mRNA, which is essential for migration to secondary lymphoid tissues (Scandella et al., 2002; Cote et al., 2009). Kabashima et al. (2003) demonstrated that the migration of Langerhans cells in the skin to draining lymph nodes on hapten application was impaired in EP4-deficient mice, resulting in suppressed contact hypersensitivity to the hapten.

2. T Cells

a. Expression. Although the EP4 receptor is abundantly expressed in the thymus, only a few reports are available on EP4 function in the thymus and T cells. Villablanca et al. (2007) outlined the role of EP4 in the early developmental stages. They used zebrafish because it was difficult to examine the role of EP4 in mammals due to placental secretion of PGE₂. In zebrafish, EP4 was expressed at 26 hours postfertilization in the dorsal aorta-posterior cardinal vein joint region, where definitive hemopoiesis arises. EP4 was then expressed in the presumptive thymus rudiment by 48 hours postfertilization, suggesting that the EP4 receptor is the earliest thymus marker, regulating T-cell precursor development via *rag1* (Villablanca et al., 2007).

Messenger RNAs for EP2, EP3, and EP4, but not EP1, were detected in antigen-specific CD4⁺ human T cells (Okano et al., 2006). A recent study demonstrated that CD46 activation induced EP4 expression and caused a decrease in the IL-10/IFN- γ ratio in T cells, and that an EP4 antagonist reversed this effect on cytokine production after CD46 stimulation (Kickler et al., 2012). Nataraj et al. (2001) showed mRNA expression of EP1, EP2, and EP4, but not EP3, on splenic T cells and B cells in mice. Mori et al. (1996) found that EP4 in T-cell lines was downregulated by phorbol 12-myristate 13-acetate, an activator of PKC. In contrast, Raji and THP-1 monocytoid cell lines

showed marked upregulation of EP4 by phorbol 12-myristate 13-acetate, whereas levels of other PGE receptors remained unchanged (Mori et al., 1996).

b. Function. CD4⁺ T cells differentiate into three subsets of effector T cells, termed Th1, Th2, and Th17 (Zhu and Paul, 2008). Th17 was recently identified, and the involvement of Th17 cells in immune diseases, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease, has been suggested. IL-6 and transforming growth factor- β initially differentiate Th0 cells to Th17 cells. IL-23 then expands Th17 cells and stabilizes their phenotype (Korn et al., 2009).

There are many reports suggesting a Th1-suppressive action of PGE₂, as described in the previous section. Recent studies, however, suggest that PGE₂ could induce Th1 differentiation under certain conditions through EP4 (Yao et al., 2009; Sakata et al., 2010a,b). Yao et al. (2009) demonstrated that, under strengthened T-cell receptor stimulation, PGE₂ facilitated IL-12-induced Th1 differentiation at nanomolar concentrations. T-cell proliferation was not affected. This differentiation occurred through EP4 via the PI3K pathway, but not via the cAMP pathway. A possible explanation for this paradox may be the different concentrations of PGE₂. At higher concentrations, PGE₂ exerts its well known Th1-suppressive effect, whereas its Th1 differentiation-promoting activity, which is robust at lower concentrations, is masked. Furthermore, these studies demonstrated that EP4-cAMP-Epac signaling promoted IL-23 production in dendritic cells, and that, in the presence of IL-23, PGE₂ facilitates the expansion of the Th17 subset of both human and mouse T cells via the EP4-cAMP-PKA pathway (Yao et al., 2009; Sakata et al., 2010b). Other types of studies also demonstrated EP4-mediated Th17 expansion (Gagliardi et al., 2010; Sakata et al., 2010a). Th17 cell differentiation was also controlled by the retinoic acid receptor-related orphan receptor- γ t. PGE₂ may positively synergize with IL-1 and IL-23 to upregulate retinoic acid receptor-related orphan receptor- γ t (Boniface et al., 2009; Napolitani et al., 2009).

Studies using animal models of Th1- and Th17-related diseases, such as autoimmune encephalomyelitis, contact hypersensitivity, colitis, and arthritis, also demonstrated that PGE₂-EP4 signaling promoted Th1 differentiation and Th17 expansion. Yao et al. (2009) demonstrated that an EP4 antagonist reduced disease severity and decreased accumulation of antigen-specific Th1 and Th17 cells in regional lymph nodes in animal models of autoimmune encephalomyelitis and contact hypersensitivity. Based on these results, the same group further demonstrated that PGE₂ exerted dual functions in experimental autoimmune encephalomyelitis. It facilitated Th1 and Th17 cell generation through EP4 during immunization, and it limited the invasion of these cells into the brain by protecting the blood-brain barrier through EP4 (Esaki et al.,

2010). Sheibanie et al. (2007a,b) have reported that stimulation of EP4 with misoprostol exacerbated both 2,4,6-trinitrobenzene sulfonic acid-induced colitis and collagen-induced arthritis in mice. It also upregulated the expression of IL-23 and IL-17 in lesions (Sheibanie et al., 2007a,b). These *in vivo* studies suggested that PGE₂-EP4 signaling could promote development of the Th1 and Th17 subsets (Table 3). Since the local concentration of PGE₂ may vary with disease type and stage, EP4 signaling cannot be simply classified as anti-inflammatory or proinflammatory.

3. Other Immune Cells

Eosinophil extravasation across the endothelium and its accumulation in tissues are hallmarks of allergic inflammation. EP4 may inhibit migration and adhesion of eosinophils (Table 3). In human eosinophils, EP4 mRNA was highly expressed (Mita et al., 2002; Luschnig-Schratl et al., 2011). The selective EP4 agonist ONO-AE1-329 potently attenuated the chemotaxis of human peripheral blood eosinophils through the PI3K pathway, but not the cAMP pathway (Luschnig-Schratl et al., 2011). PGE₂ and the EP4 agonist ONO-AE1-329 significantly reduced eotaxin-induced eosinophil adhesion to fibronectin and the formation of filamentous actin- and gelsolin-rich adhesive structures. They also reduced eosinophil transmigration across thrombin- and TNF- α -activated endothelial cells (Konya et al., 2011).

EP4 receptors are present in various B cell lines at different maturation stages (Fedyk et al., 1996). B cell receptor signaling contributes to the pathogenesis of B cell malignancies, and most B cell lymphomas depend on B cell receptor signals for survival. Murn et al. (2008) demonstrated that the EP4 receptor was downregulated in human B cell lymphoma. Stable knockdown of the EP4 receptor in B cell lymphoma markedly accelerated tumor spread in mice, whereas EP4 overexpression yielded protection against tumor spread (Murn et al., 2008). These data suggest that EP4 plays a principal role in the growth-suppressive effect of PGE₂ in B cell lymphoma. Consistently, PGE₂-EP4 signaling promoted B cell receptor-induced G₀/G₁ arrest in the B cell line WEHI 231. Thus, caspase-mediated, B cell receptor-induced apoptosis was induced (Priatelj et al., 2011). In mouse peritoneal neutrophils, not only did EP4 suppress growth, it also suppressed TNF- α production (Yamane et al., 2000). EP4 also prevented *N*-formyl methionyl leucyl phenylalanine-stimulated aggregation of rat neutrophils (Wise, 1998).

D. Osteoarticular System

1. Expression. EP4 receptors have been found in rats (Sarrazin et al., 2001) and mice (Miyaura et al., 2000; Suzawa et al., 2000) through primary culture of osteoblasts and various osteoblastic cell lines, including MCT3T3-E1, and bone marrow stromal cell

cultures (Suda et al., 1996; Weinreb et al., 1999, 2001; Sarrazin et al., 2001;). Miyaura et al. (2000) demonstrated that mouse osteoblasts isolated from calvariae expressed transcripts of all four receptors, ranked according to expression level as follows: EP4 > EP1 > EP2 > EP3. EP4 receptors are also strongly expressed in primary cultures of human osteoblasts (Sarrazin et al., 2001). In human osteoblasts, only EP4 and EP3 were observed immunohistochemically (Fortier et al., 2004).

Osteoclasts have also been shown to express EP4 abundantly (Mano et al., 2000). Although there are convincing *in vitro* and *in vivo* collective data indicating that EP2 receptors may have a role in PGE₂-mediated RANKL expression and anabolic effects on bone, to date no functional EP2 receptors have been identified on human osteoblasts or osteoclasts (Akhter et al., 2001; Li et al., 2002; Woodward et al., 2011). In human chondrocytes, EP4, EP1, and EP2 were detected (Watanabe et al., 2009).

In inflammatory bone diseases, expression of the EP4 receptor appears to be increased. In human rheumatoid synovial fibroblasts, EP4 receptors together with EP2 receptors are consistently expressed (Yoshida et al., 2001; Mathieu et al., 2008; Kojima et al., 2009). It has been reported that the EP4 receptor was upregulated in human osteoarthritis cartilage (Attur et al., 2008). The inflammatory cytokine IL-1 β also increased the expression of COX-2 and the EP4 receptor in cultured human (Watanabe et al., 2009) and rabbit chondrocytes (Alvarez-Soria et al., 2007).

2. Function. Bone remodeling, comprising the resorption of existing bone by osteoclasts and *de novo* bone formation by osteoblasts, is required for bone homeostasis. PGE₂ is known to promote both bone resorption and bone formation (Flanagan and Chambers, 1992; Scutt et al., 1995). Such effects are suggested to be mediated by EP4 signaling (Table 4).

a. Osteoblasts. It has been shown that PGE₂ stimulates osteoblastic differentiation from bone marrow-derived cells (Shamir et al., 2004; Alander and Raisz, 2006), leading to increased osteoblast numbers and bone formation. PGE₂ also induced the expression of Runt-related transcription factor 2 (Runx2) and enhanced the formation of mineralized nodules in a culture of bone marrow cells from wild-type mice but not in a culture of cells from EP4-deficient mice (Yoshida et al., 2002). This positive effect of EP4 on osteoblast differentiation was supported by several subsequent pharmacological studies. Studies using EP4 agonists (ONO-AE1-329 or ONO-4819) or EP4 antagonists (L-161,982) have shown that EP4 activation induces osteoblast differentiation of murine calvarial osteoblastic cells (Alander and Raisz, 2006), rat and mouse bone marrow stromal cells (Keila et al., 2001; Shamir et al., 2004; Nakagawa et al., 2007), and

the multipotent mesenchymal cell line C3H10T1/2 (Ninomiya et al., 2011).

A number of studies have suggested that the anabolic effect of PGE₂ is linked to an elevated level of cAMP (Hakeda et al., 1986; Graham et al., 2009), and that EP4 activation increases cAMP in osteoblasts (Sakuma et al., 2004). Runx2 and osterix are osteoblast-specific transcription factors essential for the development of osteoblastic cells and bone formation. Forskolin, an AC activator, also enhanced Runx2 and osterix transcription, but the stimulatory effects of forskolin were blocked by pretreatment of the cells with H-89, a PKA inhibitor (Wang et al., 2006a). Alkaline phosphatase activity is also a marker of osteoblast differentiation. PGE₁ increases alkaline phosphatase activity through the cAMP-PKA-p38 MAPK pathway in osteoblasts (Kakita et al., 2004). Nakagawa et al. (2007) demonstrated that the EP4 agonist ONO-4819 accelerated bone morphogenetic protein-induced osteoblast differentiation of bone marrow stromal cells. Acceleration of bone morphogenetic protein activity by the EP4 agonist was abolished by pretreatment with PKA inhibitor, but not with PKC, MAPK, or PI3K inhibitors (Nakagawa et al., 2007). These data support the concept that PGE-EP4 signaling promotes osteoblast differentiation primarily through cAMP-PKA signaling.

b. Osteoclasts. PGE₂ is a strong stimulator of osteoclast differentiation in marrow cultures and of bone resorption in bone organ culture (Blackwell et al., 2010). The major effect of PGE₂ on resorption is generally considered to occur indirectly via upregulation of RANKL expression and by inhibition of osteoprotegerin expression in osteoblastic cells (Blackwell et al., 2010). It has been suggested that PGE₂ enhances osteoclast formation through EP4 receptor activation on osteoblasts (Mano et al., 2000; Sakuma et al., 2000). Osteoclast formation was enhanced by the presence of an EP4 agonist in coculture of mouse primary osteoblastic cells and bone marrow cells, but not in cocultures of primary osteoblastic cells from EP4 KO mice (Sakuma et al., 2000). When osteoblasts are absent, EP4 agonists have an inhibitory effect on osteoclast formation and subsequently on bone resorption (Mano et al., 2000). PGE₂-induced RANKL expression was significantly reduced in primary osteoblastic cells derived from EP4 KO mice compared with those from wild-type mice (Li et al., 2002). An EP4 antagonist inhibited PGE₂-induced RANKL expression in osteoblasts, thereby increasing osteoclast differentiation *in vitro* (Tomita et al., 2002). Taken together, these data indicate that osteoblast-mediated osteoclast activation may occur through the EP4-induced activation of RANKL.

c. Bone resorption. In keeping with the data on EP4-mediated osteoclastogenesis, several reports suggest that EP4 signaling induces bone resorption in

TABLE 4
Reported roles of EP4-mediated signaling pathways in the osteoarticular system

Tissues/Diseases	Reported Functions	Proposed Effector Pathway(s)	Pathophysiologic Process	References
Bone	Osteoblast differentiation	N.D.	Runx2 expression	Yoshida et al., 2002
	Osteoblast differentiation	PKA	N.D.	Nakagawa et al., 2007
	Osteoblast differentiation	N.D.	N.D.	Keila et al., 2001; Shamir et al., 2004; Alander and Raisz, 2006 Gao et al., 2009; Ninomiya et al., 2011
	Osteoclast differentiation	cAMP	RANKL expression	Tomita et al., 2002
	Osteoclast differentiation	N.D.	N.D.	Ono et al., 1998
	Bone formation	N.D.	N.D.	Machwate et al., 2001; Hagino et al., 2005; Li et al., 2005; Toyoda et al., 2005 Akhter et al., 2006; Ito et al., 2006; Ke et al., 2006; Onishi et al., 2008 Suzawa et al., 2000
	Bone resorption	cAMP	Osteoclast differentiation factor expression	
	Bone resorption	cAMP	MMP-2, MMP-13 expression	Miyaura et al., 2000
	Bone resorption	cAMP	N.D.	Mano et al., 2000
	Bone resorption	N.D.	Osteoclast differentiation factor expression Inhibition of osteoclastogenesis inhibitory factor	Sakuma et al., 2000
	Bone resorption	N.D.	RANKL expression	Li et al., 2002
	Bone resorption	N.D.	N.D.	Zhan et al., 2005
	Bone healing	N.D.	MMP-9 expression	Xie et al., 2009
Bone healing	N.D.	N.D.	Tanaka et al., 2004; Li et al., 2005; Marui et al., 2006	
Cartilage	Endochondral bone formation	cAMP	Chondrocyte differentiation	Miyamoto et al., 2003b
	Matrix degradation and inhibition of proteoglycan synthesis	N.D.	MMP-13, ADAMTS-5 expression	Attur et al., 2008
Rheumatoid arthritis	Development of arthritis	PKA; p38 MAPK	COX-2 expression in synovial fibroblasts	Faour et al., 2001
	Development of arthritis	N.D.	PTH-related peptide production in synovial fibroblasts	Yoshida et al., 2001
	Development of arthritis	N.D.	IL-1 β and IL-6 production in macrophages	McCoy et al., 2002
	Development of arthritis	N.D.	Th1 differentiation and Th17 expansion	Chen et al., 2010
	Development of arthritis	N.D.	N.D.	Murase et al., 2008
	Development of arthritis	N.D.	N.D.	Okumura et al., 2008
Development of arthritis	N.D.	N.D.	Honda et al., 2006	

ADAMTS-5, a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 5; N.D., not determined; PTH, parathyroid hormone.

vitro. Induction of bone resorption by PGE₂ was greatly impaired in cultured calvariae from EP4-deficient mice, but not in those from EP1-, EP2-, or EP3-deficient mice (Miyaura et al., 2000; Zhan et al., 2005). Similar results have been obtained in studies using pharmacological approaches. An EP4 agonist stimulated bone resorption in organ culture of rodent calvaria (Suzawa et al., 2000; Raisz and Woodiel, 2003), and the EP4 antagonist AH23848B inhibited osteoclastogenesis in mouse marrow culture (Ono et al., 1998). These in vitro data suggest that EP4 activation has a resorptive effect, associated with increased osteoclastic differentiation and osteoclastogenesis.

Although reports on the signaling pathway used by EP4 in osteoclast activation are limited, Miyaura et al. (2000) demonstrated that both PGE₂ and dibutyl cAMP stimulated bone resorption and induced MMP-2 and MMP-13 in cultured calvariae, and that the

addition of H-89, an inhibitor of PKA, or BB94, an inhibitor of MMPs, significantly suppressed the bone-resorbing activity induced by PGE₂. Furthermore, dibutyl cAMP greatly stimulated bone resorption and MMP-2 and MMP-13 in both wild-type and EP4-knockout mice (Miyaura et al., 2000). Kaji et al. (1996) also reported that the activation of PKA is linked to PGE₂-stimulated osteoclast-like cell formation and bone-resorbing activity. These findings suggest that PGE₂ stimulates bone resorption by a cAMP-PKA-dependent mechanism via the EP4 receptor.

d. Bone anabolism. Since EP4 plays a role in both osteoblast differentiation and osteoclast activation in vitro, the bone-anabolic and bone-resorptive effects of EP4 have been extensively studied in vivo. There is a disagreement among studies concerning the effects of EP4 deletion. Akhter et al. (2006) reported that aged EP4-deficient female mice had small distal femur and

vertebral bone volumes and exhibited reduced structural and apparent material strength in the femoral shaft and vertebral body. Similarly, bone mass was reduced in aged EP4-deficient male mice (Li et al., 2005). On the other hand, a study using mice with global or osteoblast-targeted deletion of the EP4 receptor suggested that EP4 activation induced osteoblast differentiation in vitro, although its activation is not essential for bone volume or bone formation in living animals (Gao et al., 2009). The mechanisms underlying this disagreement are not clear, but the loss of EP4 may be differentially compensated in various strains of genetically modified mice.

Contrary to this discrepancy between studies using genetically modified mice, most studies using pharmacological approaches have suggested that EP4 activation has anabolic effects in bone. EP4 agonists (ONO-4819) delivered via local or systemic administration increased bone mass and strength in intact rats (Ninomiya et al., 2011) and in ovariectomized rats as an osteoporosis model (Yoshida et al., 2002; Ito et al., 2006; Ke et al., 2006). In a different model of osteoporosis induced through immobilization, ONO-4819 also completely blocked bone loss in rats when infused systemically (Yoshida et al., 2002). ONO-4819 in rats enhanced mechanical loading-induced cortical bone formation (Hagino et al., 2005). Pharmacological inactivation of EP4 in rats suppressed PGE₂-induced bone formation (Machwate et al., 2001; Shamir et al., 2004). Another study showed that an EP4 agonist enhanced bone formation around titanium plates, suggesting that the EP4 agonist promotes early bone formation in the bone-implant interface (Onishi et al., 2008). It is worth noting that recent studies have suggested that attenuated G_sα coupling to AC contributed to age-related decreases in bone formation (Kessler and Delany, 2007; Genetos et al., 2012). Osteoporosis is a systemic skeletal disorder characterized by a reduction in bone mineral density and disruption in bone microarchitecture. Since there are a large number of affected patients, many people would benefit from a potential treatment of osteoporosis incorporating an EP4 agonist.

e. Bone healing. Several in vivo studies have also investigated the potential therapeutic effect of EP4 agonists in facilitating bone healing (Tanaka et al., 2004; Marui et al., 2006). EP4 receptor knockout mice have been shown to have impaired fracture healing (Li et al., 2005). Administration of an EP4 agonist promoted healing of the sternum filled with regenerated bone tissue and increased bone mineral content and density in diabetic rats (Marui et al., 2006). Similarly, the EP4 agonist ONO-4819 dose-dependently accelerated the healing of a cortical bone defect at the drill-hole site by stimulating local bone resorption and formation (Tanaka et al., 2004). Toyoda et al. (2005) used a local drug delivery system and found that the

EP4 agonist ONO-4819 in a carrier polymer enhances bone morphogenetic protein-induced bone formation in mice. Furthermore, an EP4 agonist accelerated delayed fracture healing in aged mice and compensated for the reduced fracture healing observed in COX-2 KO mice (Xie et al., 2009). These data collectively suggest that bone formation is more likely than bone resorption to be promoted by EP4 in vivo. EP4 activation appears to play beneficial roles in osteoporosis and fracture healing through cAMP signaling.

f. Rheumatoid arthritis and other diseases. A substantial body of evidence suggests that PGE₂ contributes to the pathogenesis of rheumatoid arthritis (Akaogi et al., 2006; Hikiji et al., 2008), and inhibitors of PGE₂ synthesis are currently used in the treatment of this disease. Rheumatoid arthritis is characterized by chronic joint inflammation comprising synovial fibroblasts, T cells, and macrophages (Sato and Takayanagi, 2006). T cells activate synovial macrophages that release multiple cytokines, resulting in the amplification of synovial inflammation and the destruction of cartilage and bone. Macrophage-derived cytokines such as IL-1β and TNF-α induce COX-2 expression in human articular chondrocytes and synovial fibroblasts (Martel-Pelletier et al., 2003). IL-17 also stimulates COX-2-dependent PGE₂ synthesis in mouse primary osteoblasts from the synovial tissues (Kotake et al., 1999).

The roles of PGE₂ and EP4 receptor signaling in rheumatoid arthritis have been extensively examined using multiple animal models, such as collagen-induced arthritis (CIA), collagen antibody-induced arthritis (CAIA), and adjuvant-induced arthritis (Table 4). Mice deficient in COX-2 or PGE₂ synthase 1 are resistant to CIA and CAIA (Myers et al., 2000; Hegen et al., 2003; Trebino et al., 2003; Kamei et al., 2004). PGE₂ has also been shown to exacerbate symptoms in CIA through the inflammatory Th17/IL-17 axis (Sheibanie et al., 2007a). EP4-deficient mice, but not EP1-, EP2-, or EP3-deficient mice, showed decreased inflammation, as evidenced by decreased circulating IL-6 and serum amyloid A levels, as well as by the reduced incidence and severity of disease in CAIA (McCoy et al., 2002). In this study, macrophages isolated from EP4 KO animals produced significantly less IL-1β and IL-6 than control samples did, suggesting that EP4 signaling in macrophages contributes to the exacerbation of rheumatoid arthritis (McCoy et al., 2002).

In keeping with this study, pharmacological blockade of EP4 signaling ameliorates rodent models of rheumatoid arthritis. Administration of EP4 antagonists (ER819762, CJ-042794, or CJ-023423) effectively suppressed disease in CIA and adjuvant-induced arthritis (Murase et al., 2008; Okumura et al., 2008; Chen et al., 2010). Chen et al. (2010) suggested that the EP4 antagonist used in their study suppressed the ability of lymph node T cells to produce IFN-γ and IL-17 ex vivo in response to stimulation with bovine type

II collagen/Complete Freund's adjuvant. Significant suppression of CIA is achieved in mice by the simultaneous inhibition of EP2 and EP4 receptors, although the EP4 antagonist ONO-AE3-208 alone did not alter CIA in wild-type mice (Honda et al., 2006). Several studies have shown the involvement of EP4 signaling in cytokine-related action in human synovial fibroblasts (Faour et al., 2001; Yoshida et al., 2001; Mathieu et al., 2008). Taken together, most studies suggest that EP4 antagonists ameliorate rheumatoid arthritis in multiple cell types, including T cells, macrophages, and synovial fibroblasts, and are potentially beneficial in the treatment of rheumatoid arthritis.

Periprosthetic osteolysis is the most common cause of aseptic loosening in total joint arthroplasty. Synovial fibroblasts respond directly to titanium particles, increasing RANKL expression through a COX-2/PGE₂/EP4/PKA signaling pathway and enhancing osteoclast formation (Wei et al., 2005). Tsutsumi et al. (2009) examined the role of EP4 in periprosthetic fibroblasts using mice with conditionally deleted EP4 in FSP1-positive fibroblasts and found that polyethylene-bead-induced osteolysis is impaired in conditional EP4 KO mice. They concluded that fibroblasts rather than osteoblasts are the predominant source of RANKL (Tsutsumi et al., 2009). These data suggested that EP4 signaling in synovial fibroblasts plays a role in osteolysis after joint arthroplasty.

g. Chondrocytes. Chondrocytes are involved in endochondral bone formation as well as coordinated bone formation and mineralized matrix resorption by osteoblasts and osteoclasts. Reports on the role of the EP4 receptor in chondrocytes are limited (Table 4). In the growth plate, chondrocytes undergo a maturation process, in which resting chondrocytes transition into proliferating chondrocytes, which express type II collagen mRNA and synthesize proteoglycan. It has been reported that EP4 receptor stimulation accelerates the maturation of mouse and rat chondrocytes (Miyamoto et al., 2003b; Clark et al., 2005). In contrast, PGE₂ inhibits proteoglycan synthesis and stimulates matrix degradation via the EP4 receptor in chondrocytes from patients with osteoarthritis (Attur et al., 2008).

E. Gastrointestinal Tract

1. Expression. The EP receptors have distinct cellular localizations in the mouse gastrointestinal tract (Morimoto et al., 1997). The EP4 receptor is moderately expressed in the mouse and rat stomach (Honda et al., 1993; Sando et al., 1994; Sugimoto and Narumiya, 2007) and in the rat gastric mucosal cell line RGM1 (Suetsugu et al., 2000). Expression of EP4 mRNA was localized in mouse (Morimoto et al., 1997) and rabbit (Takahashi et al., 1999) epithelial cells of

the corpus and in glands from the surface to the base of the gastric antrum.

In the ileum, the EP4 receptor is highly expressed in humans, mice, and rats (An et al., 1993; Honda et al., 1993; Bastien et al., 1994; Sando et al., 1994; Ding et al., 1997). The EP4 receptor is also highly expressed in the human, mouse, and rat colon (An et al., 1993; Ding et al., 1997; Kabashima et al., 2002; Olsen Hult et al., 2011). A recent study examined the precise distribution of the EP receptors in the intestinal epithelium in humans (Olsen Hult et al., 2011). This study demonstrated that the EP4 and EP2 receptors were expressed in normal colon epithelial crypt cells, but not in normal small intestinal epithelium. The inflamed duodenal epithelium from patients with untreated celiac disease expressed EP4 and EP2 in crypt cells. On the other hand, the EP1 and EP3 receptors were not detected in intestinal epithelium (Olsen Hult et al., 2011).

In contrast to its abundant expression in the colon epithelium, the EP4 receptor was not found in the intestinal smooth muscle layer in mice, rats, or humans (Ding et al., 1997; Morimoto et al., 1997; Olsen Hult et al., 2011). Other EP receptors have been found in the muscle layer of the gastrointestinal tract. mRNA expression of the EP1 receptor has been found in the muscularis mucosae layer of the stomach (Watabe et al., 1993; Morimoto et al., 1997) and in colonic longitudinal muscle (Smid and Svensson, 2009). EP3 receptor mRNA has been found in longitudinal smooth muscle cells and in neurons of the myenteric ganglia (Narumiya et al., 1999). These observations suggest that EP4 receptor signals contribute to epithelial function rather than smooth muscle tone.

The EP4 receptor has been found to be upregulated in inflammatory bowel disease. Expression of the EP4 receptor was strongly upregulated in rats with dextran sodium sulfate-induced colitis (Ding et al., 1997; Nitta et al., 2002). Consistently, Lejeune et al. (2010) have reported that, in healthy human colonic mucosa, EP4 receptors were localized on apical plasma membranes of epithelial cells at the tips of mucosal folds; in patients with inflammatory bowel disease and in rats with dextran sodium sulfate-induced colitis, on the other hand, they were diffusely overexpressed throughout the mucosa.

2. Function. NSAIDs have been widely used to achieve analgesic and anti-inflammatory effects, but a major limitation to their use is their potential to cause damage to the gastrointestinal mucosa (Levi et al., 1990; Tanaka et al., 2002). The healing-impairing effect of the NSAIDs is due to their inhibition of COX, especially COX-2 (Tanaka et al., 2002; Takeuchi et al., 2010a). EP4 activation has been found to attenuate indomethacin-induced intestinal ulcers in rats (Kunikata et al., 2002; Hatazawa et al., 2006; Takeuchi et al., 2010b). A substantial body of evidence

suggests that EP4 plays a role in maintaining gastrointestinal integrity.

a. Mucin secretion. PGE₂ increases gastric mucin secretion and suppression of motor action, and these activities are quite effective in the prevention of gastric mucosal injury (Takeuchi et al., 2010a). It has been reported that EP4 activation promotes mucin secretion from gastric epithelial cells (Takahashi et al., 1999). Similarly, EP4-mediated increases in mucus secretion and intestinal fluid secretion have been found to contribute to the process of intestinal ulcer healing (Kunikata et al., 2002). It has also been reported that cAMP contributes to gastrointestinal mucin secretion, including its principal functional component, mucus glycoprotein (Keates and Hanson, 1990; Slomiany and Slomiany, 2005). Slomiany and Slomiany (2005) demonstrated that β -adrenergic GPCR activation and subsequent AC activation triggered mucin secretion via both the PKA and PI3K pathways. From these data, it is speculated that EP4 activation promotes gastrointestinal mucin secretion through the cAMP pathway.

b. Mucosal cell injury. Several in vivo studies suggested that EP4 activation plays a protective role in rodent models of gastric ulcer via different mechanisms, such as VEGF induction, venous relaxation, and inhibition of apoptosis (Hatazawa et al., 2007; Hattori et al., 2008; Jiang et al., 2009), although there are reports that EP4 did not contribute to ulcer healing (Kunikata et al., 2001; Takeuchi et al., 2003).

Takeuchi et al. (2010b) found that an EP4 agonist reversed indomethacin-induced downregulation of VEGF expression and angiogenesis, and suggested that endogenous PGE₂ promotes the healing of small intestinal lesions by stimulating angiogenesis through the upregulation of VEGF expression mediated by the activation of EP4 receptors. It has also been reported that EP4 activation promotes VEGF production from gastric fibroblasts (Takahashi et al., 1996; Hatazawa et al., 2007). A study using human airway smooth muscle cells revealed that EP4 signaling increases VEGF transcriptionally and involves the Sp-1 binding site via a cAMP-dependent mechanism (Bradbury et al., 2005).

Hoshino et al. (2003) demonstrated that EP4 activation inhibited ethanol-induced apoptosis in primary culture of guinea pig gastric mucosa cells through the cAMP-PKA pathway, but not the PI3K pathway. Similar results were shown in indomethacin-induced apoptosis in human gastric mucosa cells (Jiang et al., 2009). An antiapoptotic effect of cAMP has also been demonstrated in the T84 intestinal epithelial cell line (Nishihara et al., 2003; Rudolph et al., 2004, 2007). By use of pharmacological activators and inhibitors of PKA as well as siRNA, Rudolph et al. (2007) demonstrated that cAMP binding to the PKAII regulatory subunit leads to the subsequent phosphorylation of

ERK1/2, resulting in inhibition of epithelial apoptosis. EP4-cAMP signaling appears to play protective roles in mucosal cell injury via induction of VEGF and inhibition of apoptosis.

c. HCO₃⁻ secretion. Duodenal mucosal HCO₃⁻ secretion is critical to prevent acid peptic injury. PGE₂ increases HCO₃⁻ secretion from the rat duodenal mucosa (Takeuchi et al., 1997). It has been suggested that EP4 synergizes with EP3 to promote duodenal mucosal HCO₃⁻ secretion (Takeuchi et al., 2010a). Studies have demonstrated that duodenal HCO₃⁻ secretion is stimulated by the EP4 agonist ONO-AE1-329 under HCl-induced mucosal acidification conditions (Aoi et al., 2004; Aihara et al., 2007). The maximal response of the EP4 agonist was equivalent to that induced by PGE₂. Coadministration of the EP1/3 agonist sulprostone and ONO-AE1-329 caused a greater secretory response than either agent alone, suggesting that EP4 receptors together with EP3 receptors are involved in the duodenal HCO₃⁻ response induced by PGE₂ (Aoi et al., 2004).

The stimulatory effect of PGE₂ on duodenal HCO₃⁻ is mediated intracellularly by cAMP, PI3K, and Ca²⁺ (Tuo et al., 2007; Takeuchi et al., 2011). Although there is no direct evidence that a downstream signaling mechanism of EP4 is involved in duodenal HCO₃⁻ response, several studies have suggested that EP4 receptor signaling and EP3 receptor signaling could act in coordination to maintain duodenal mucosal integrity against acid through intracellular cAMP and PI3K and Ca²⁺ elevation. Tuo et al. (2007) demonstrated that PGE₂-stimulated duodenal HCO₃⁻ secretion was reduced by the cAMP-dependent signaling pathway inhibitors MDL-12330A (an AC inhibitor) and KT-5720 (a PKA inhibitor) by 23 and 20%, respectively; reduced by the Ca²⁺-influx inhibitor verapamil by 26%; reduced by the calmodulin antagonist W-13 by 24%; and reduced by the PI3K inhibitors wortmannin and LY-294002 by 51 and 47%, respectively. Similarly, elevation of intracellular cAMP levels by the non-selective PDE inhibitor 3-isobutyl-1-methylxanthine, the PDE1 inhibitor vinpocetine, and the PDE3 inhibitor cilostamide increased HCO₃⁻ secretion in duodenal mucosa (Hayashi et al., 2007; Takeuchi et al., 2011, 1997).

d. Colitis. The protective effect of EP4 on the colon has been shown in in vivo studies using mouse and rat dextran sodium sulfate-induced colitis. Kabashima et al. (2002) used mice deficient in EP1, EP2, EP3, or EP4 and found that only EP4-deficient mice suffered from exacerbated 3% dextran sodium sulfate-induced colitis with impaired mucosal barrier function, epithelial loss, crypt damage, and accumulation of neutrophils and CD4⁺ T cells. Consistent with this observation, administration of an EP4-selective agonist (ONO-AE1-734) in wild-type mice ameliorated severe colitis induced with 7% dextran sodium sulfate. This study

focused on immune response induced by EP4 signaling and demonstrated in vitro that the EP4 antagonist ONO-AE3-208 enhanced, whereas the EP4 agonist ONO-AE1-734 suppressed, the proliferation of and Th1 cytokine production by lamina propria mononuclear cells from the colon (Kabashima et al., 2002). Similarly, Nitta et al. (2002) reported that the EP4 agonist ONO-AE1-329 suppressed rat dextran sodium sulfate-induced colitis through upregulation of the anti-inflammatory cytokine IL-10. Jiang et al. (2007) demonstrated that treatment with the EP4 agonists ONO-AE1-329 or AGN205203 ameliorated a murine model of colitis, and that EP4 activation decreased colon epithelial apoptosis, prevented goblet cell depletion, and promoted epithelial regeneration in vitro. These studies suggest that EP4 maintains gastrointestinal homeostasis by preserving mucosal integrity and downregulating inflammatory immune response.

e. Inflammatory bowel disease. In contrast to its protective effect on gastrointestinal mucosal integrity, more recent studies have suggested that the EP4 receptor plays proinflammatory roles in inflammatory bowel disease. Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, is chronic and relapsing and is characterized by inflammation in the large and/or small intestine associated with diarrhea, occult blood, and abdominal pain. Studies in humans have implicated impaired mucosal barrier function, production of proinflammatory cytokines, and activation of CD4+ T cells in the pathogenesis of inflammatory bowel disease (Fiocchi, 1998). It is known that PGE₂ is produced abundantly and that EP4 is upregulated in the affected intestine (Hommes et al., 1996; Lejeune et al., 2010). Furthermore, in a genome-wide association study of Caucasian patients with Crohn's disease, Libioulle et al. (2007) identified a region of approximately 250 kb on chromosome 5p13.1. Studies in lymphoblastoid cell lines revealed that genetic variants in the Crohn's disease-associated region influence the expression levels of the closest known gene, PTGER4, located 270 kb away in the direction of the centromere. This study suggested that genetic variants associated with Crohn's disease on chromosome 5p13.1 could modulate *cis*-acting regulatory elements of PTGER4 (Libioulle et al., 2007). From these observations, EP4 is likely to regulate Crohn's disease initiation and progression.

Th17 cells have emerged recently as central players in various inflammatory/autoimmune conditions, including inflammatory bowel disease (Yen et al., 2006). Crohn's disease patients have increased levels of IL-17 in serum and intestinal mucosa (Fujino et al., 2003b; Nielsen et al., 2003; Fuss et al., 2006). In accordance with these data, Sheibanie et al. (2007b) demonstrated that the PGE analog misoprostol exacerbated 2,4,6-trinitrobenzene sulfonic acid-induced colitis and that

this exacerbation was correlated with an increase in IL-23 and IL-17, a decrease in IL-12p35 expression in the colon and mesenteric lymph nodes, and a substantial increase in the numbers of infiltrating neutrophils and Th17 cells in the colonic tissue. The study demonstrated that PGE₂ promotes IL-23 and inhibits IL-12 and IL-27 expression through EP4 in dendritic cells in vitro, suggesting that PGE₂ exacerbates the inflammatory process through the release of dendritic cell-derived IL-23 and the subsequent support of the autoreactive/inflammatory Th17 phenotype (Sheibanie et al., 2007b). Taken together, these data suggest that increased expression and subsequent activation of EP4 contribute to exacerbation of Crohn's disease through enhancement of the Th17 immune response.

IL-8 is a potent neutrophil chemoattractant and activator, and its levels correspond to the active grade of inflammatory bowel disease, including ulcerative colitis and Crohn's disease (Mazzucchelli et al., 1994). Srivastava et al. (2012) examined the mechanisms of differential regulation of IL-8 production by EP4 and demonstrated that PGE₂-EP4 signaling activated CREB through both the PKA and PI3K pathways. Interestingly, they also demonstrated that EP2 activated the transcription factor-inducible cAMP early repressor (Srivastava et al., 2012). Because inducible cAMP early repressor lacks the transactivation domain, it functions as a transcription repressor, unlike CREB. These data suggest that PGE₂ coupling through EP4 and EP2 receptors can therefore act in an opposing manner to either promote (EP4) or decrease (EP2) IL-8 expression, even though both receptors use the same second messenger, cAMP. Since Chadee's laboratory has reported that PGE₂ promotes IL-8 production in the human colonic epithelial cell lines Caco-2 and T84 through both the PKA and PI3K pathways (Dey and Chadee, 2008; Dey et al., 2009; Srivastava et al., 2012), it appears that EP4 contributes to IL-8 production.

f. Epithelial barrier. More recent data have suggested that colonic epithelial barrier function is disrupted by EP4 signaling in Caco-2 and T84 cells (Lejeune et al., 2010, 2011; Rodriguez-Lagunas et al., 2010). It has been reported that EP4 signaling increased intracellular Ca²⁺ concentration through the cAMP-PKA pathway, resulting in disruption of the colonic epithelial barrier in vitro (Rodriguez-Lagunas et al., 2010). Recently, several authors have described the cross-talk relationship between IP₃ receptors/Ca²⁺ release and the cAMP-PKA signaling pathway. Phosphorylation of IP₃ receptors by PKA results in a significant enhancement of IP₃-induced intracellular Ca²⁺ and is involved in diverse Ca²⁺-regulated physiologic processes (Bruce et al., 2002; Tang et al., 2003; Chaloux et al., 2007). Wagner et al. (2008) demonstrated that PKA phosphorylation increases the

sensitivity of the IP₃ receptor to IP₃. Intestinal epithelial barrier function may be regulated by these mechanisms.

Collectively, the evidence indicates that EP4 signaling maintains gastrointestinal homeostasis by preserving mucosal function in physiologic settings. However, in chronic inflammatory bowel disease such as Crohn's disease, EP4 signaling is suggested to promote intestinal inflammation.

F. Renal System

1. Expression. Northern blot analysis demonstrated moderate but significant expression of the EP4 receptor in the kidneys of humans (An et al., 1993; Bastien et al., 1994), mice (Sugimoto and Narumiya, 2007), rats (Sando et al., 1994), and rabbits (Breyer et al., 1996b). In situ hybridization studies have revealed that the EP4 receptor is highly expressed in the glomerulus (Sugimoto et al., 1994). The EP3 receptor, on the other hand, is expressed in the tubular epithelium, the thick ascending limb, and the cortical collecting ducts in the outer medulla. The EP1 receptor is expressed in the papillary collecting ducts. Similarly, EP4 receptor mRNA is predominantly expressed in the glomerulus in humans (Breyer et al., 1996b) and rabbits (Breyer et al., 1996a; Morath et al., 1999), suggesting that EP4 contributes to the regulation of glomerular hemodynamics and renin release (Breyer and Breyer, 2001). In the normal and ischemic adult human kidney, vascular COX-2 was colocalized with EP4 receptors (Therland et al., 2004). In a study in rats, the EP4 receptor was strongly expressed in the glomeruli, renin-secreting juxta-glomerular granular (JG) granular cells (Jensen et al., 1999), glomerular epithelial cells (Aoudjit et al., 2006), distal convoluted tubules, cortical collecting ducts (Jensen et al., 2001), and developing renal tubules (Yamamoto et al., 2011). When rats were given low-NaCl diets, the EP4 transcripts in glomeruli were significantly increased, implicating its role in regulating NaCl homeostasis (Jensen et al., 1999).

2. Function. The dominant expression of EP4 in the glomerulus suggests that EP4 may regulate glomerular filtration. Albuminuria is a useful marker for evaluation of glomerular filtration barrier (GFB) damage. Conventionally, nonsteroidal anti-inflammatory drugs have been reported to reduce proteinuria (Vriesendorp et al., 1986), suggesting that prostanooids, derived from COX-1 or COX-2, may worsen GFB damage. The effect of EP4 receptor signaling on glomerular function has remained controversial, however.

Animal studies using podocyte-specific EP4 receptor-overexpressing or EP4 receptor-deficient mice were performed by Stitt-Cavanagh et al. (2010). They induced renal ablation by 5/6 nephrectomy, and found increased proteinuria and mortality in mice overexpressing

the EP4 receptor (Stitt-Cavanagh et al., 2010). In EP4-deficient mice, however, proteinuria was decreased and glomerular lesions became milder. A COX-2 inhibitor also decreased proteinuria. They also found that EP4 receptor overexpression in cultured podocytes resulted in enhanced susceptibility to mechanical stretch-induced detachment from culture dishes, which may be a potential mechanism leading to the pathogenesis of proteinuria. Thus, PGE₂, acting via EP4 receptors, may progress podocyte injury and GFB damage, leading to proteinuria.

In contrast to the previous findings, Aoudjit et al. (2006) reported that an EP4 receptor antagonist worsened proteinuria and glomerular apoptosis in a rat model of podocyte injury. Similarly, Nagamatsu et al. (2006) demonstrated that an EP4 receptor agonist was protective in antiglomerulus antiserum-induced glomerulonephritis in mice. It was most likely that EP4/cAMP signaling enhanced clearance of aggregated protein from the glomeruli (Nagamatsu et al., 2006). Thus, it seems that the EP4 receptor is, at the least, involved in the development of glomerular diseases, but further studies are required to reveal its mechanistic role.

Meanwhile, EP4 may regulate renal circulation, and thus may contribute to glomerular injury. PGE₂ mediates vasodilatory effects in the preglomerular circulation; this is the mechanism by which NSAIDs reduce glomerular filtration rate and renal blood flow (Schnermann and Weber, 1982; Chaudhari et al., 1990). Edwards (1985) reported that PGE₂ exerted a vasorelaxing effect on the afferent arteriole, but not on the efferent arteriole of rabbit glomeruli.

EP4 may play a role in renin secretion. PGE₂-induced renin release through EP4 receptors in mice was demonstrated in the isolated perfused kidney (Schweda et al., 2004) and in isolated JG cells (Friis et al., 2005). These studies found that EP4 stimulation caused PKA-mediated exocytotic fusion and release of renin granules in rat JG cells. In accordance with these findings, plasma renin concentrations were significantly lower in EP4 receptor-deficient mice than in wild-type mice. Moreover, a low dose of PGE₂ failed to induce renin secretion in the isolated kidneys of EP4 receptor-deficient mice, whereas the same dose of PGE₂ enhanced renin secretion in wild-type and other EP receptor-deficient kidneys. These findings indicate that the EP4 receptor may play a critical role in the regulation of renin secretion under normal conditions. Cyclic AMP has been recognized as an important regulator of renin secretion (Hackenthal et al., 1990). Aldehni et al. (2011) reported that AC5 and AC6, which are G₃α- and Ca²⁺-inhibitable AC isoforms, are involved in the stimulatory effect of catecholamines and that PGE₂-mediated signaling is involved the secretion of renin. Isoproterenol- and PGE₂-induced renin secretion was attenuated in isolated perfused kidneys

from AC5- and AC6-deficient mice. Furthermore, EP2 stimulation caused PKA-mediated release of renin granules in rat JG cells (Friis et al., 2005). These studies suggest that renin secretion might be related to cAMP downstream of EP4 signaling.

EP4 is also expressed in the distal convoluted tubule and the cortical collecting duct (Olesen et al., 2011). A recent report demonstrated that EP4 receptor agonists increase aquaporin-2 phosphorylation and trafficking. EP4 may be involved in the regulation of water homeostasis via the regulation of water transport in the collecting duct. cAMP has been demonstrated to play an important role in the regulation of water transport in the collecting duct. Vasopressin exerts its antidiuretic effect through vasopressin 2 receptors coupled to Gs protein, which activates AC to form cAMP from ATP. Increased cAMP activates PKA, which phosphorylates aquaporin-2 water channels, thereby promoting water reabsorption (Nielsen et al., 1999). Further studies are required to determine whether EP4 is involved in the regulation of water homeostasis in the collecting duct.

G. Reproductive System

1. *Expression.* PGE₂ regulates various uterine functions, such as contraction and relaxation of the uterine smooth muscles, cervical ripening and labor induction, elevation of endometrial vascular permeability, and induction of decidualization (Murdoch et al., 1993). In female reproductive organs such as the ovary and uterus, hormonal exposure induces expression of the EP subtypes in a cell type-specific manner. EP4 is expressed in the mouse ovary (Segi et al., 2003) and in the human (Milne et al., 2001; Astle et al., 2005), baboon (Smith et al., 1998), mouse (Katsuyama et al., 1997; Yang et al., 1997), rat (Blesson et al., 2012), and guinea pig (Terry et al., 2008) uterus, although Arosh et al. (2003, 2004) reported that EP4 mRNA was undetectable in the bovine uterus.

In the mouse ovary, EP4 expression was found in oocytes in the preantral follicles. Upon gonadotropin stimulation, however, it disappeared, reappearing in both cumulus and granulosa cells 3 hours after gonadotropin stimulation. EP4 mRNA was detected in the epithelium throughout the oviduct, the tube extending from the periovarial space to the uterine horns (Segi et al., 2003).

Milne et al. (2001) examined menstrual cyclical variation in endometrial human EP receptor mRNA expression. They demonstrated that EP4 receptor expression was significantly higher in the late proliferative stage than in the early, middle, and late secretory stages. Both EP4 and EP2 receptor expression were found in endometrial glandular epithelial and vascular cells, with no notable spatial or temporal variation (Milne et al., 2001). The expression change in

pseudopregnancy was also demonstrated in the mouse uterus. The EP4 receptor transcripts were expressed mainly in the luminal epithelium during peri-implantation; they were increased in endometrial stromal cells and the glandular epithelium after pharmacological induction of pseudopregnancy (Katsuyama et al., 1997; Yang et al., 1997). EP4 transcripts were also present in the myometrium and remained unchanged throughout gestation in pregnant humans (Astle et al., 2005) and guinea pigs (Terry et al., 2008). EP3 receptor mRNA was predominantly expressed in the myometrium (Katsuyama et al., 1997; Yang et al., 1997).

The uterine cervix also plays a crucial role in pregnancy; it must remain closed during gestation, then soften and dilate during labor. PGE₂ has been used to induce cervical ripening for many years (Woodward and Chen, 2004). EP4 receptor expression has been found in smooth muscle cells and epithelial cells in the cervix, and at its highest concentration at parturition in goats (Gu et al., 2012) and rats (Chien and Macgregor, 2003; Hinton et al., 2010), suggesting that increased EP4 receptor expression may regulate cervical relaxation. EP4 receptor expression is also increased in cervical inflammation. *Chlamydia trachomatis* LGV2 selectively upregulated COX-2 and EP4 in cervical epithelial HeLa 229 cells (Fukuda et al., 2005). Similarly, EP4 receptor was increased in LPS-treated rabbit interstitial cells in the cervix (Fukuda et al., 2007) and in IL-1 β -treated human cervical fibroblasts (Schmitz et al., 2003).

EP4 receptor may be involved in the male reproductive organs as well. Moderate expression of EP4 was demonstrated in the human (An et al., 1993), bovine (Arosh et al., 2003), and chicken (Kwok et al., 2008) testis, although no EP4 expression was detectable in the mouse (Honda et al., 1993) or rat (Sando et al., 1994) testis.

2. *Function.* Myometrial relaxation is mediated by EP4 as well as by EP2 receptors (Senior et al., 1993; Negishi et al., 1995). The localization and expression of these receptors are thus involved in the onset and maintenance of labor. However, no significant pregnancy- or labor-associated changes in EP4 receptor expression were reported in the human uterus (Astle et al., 2005). The EP4 receptor is similarly expressed in the upper and lower segments of the uterus. It is most likely that EP4 does not play a major role in PGE₂-mediated regulation of myometrial tone during pregnancy and labor. Cyclic AMP may play an important role in myometrial quiescence (Yuan and Lopez Bernal, 2007). In general, PKA phosphorylates cellular proteins that may cause smooth muscle relaxation, including myosin light-chain kinase (Nishikawa et al., 1984), PDE4 (Murthy et al., 2002), and PLC. EP4 signaling may be involved in the enhancement of such phosphorylation, and it remains as yet a possibility

that EP4 is involved in other relevant processes during pregnancy and delivery. Glycosaminoglycan redistribution is an important process involved in cervical ripening; Schmitz et al. (2001) demonstrated that, of the four subtypes of PGE₂ receptors, only EP4 mediated PGE₂-induced glycosaminoglycan synthesis in human cervical fibroblasts in a PKA-independent manner.

The EP4 receptor may regulate endometrial function. PGE₂ promotes the survival of human endometrial cells through the EP4 receptors by activating ERK, Akt, NF- κ B, and the β -catenin signaling pathway (Banu et al., 2009). Inhibition of EP4 may suppress proliferation and induce apoptosis of human endometrial cells. In addition, Lee et al. (2012) found that EP4 was expressed in the ovine endometrium, especially during pregnancy. Interferon- γ , a pregnancy recognition signal in ruminants, increased EP4 receptors in the endometrium.

H. Lungs

1. Expression. The lung is an organ in which the EP4 receptor is abundantly expressed in many species, including humans, mice, rats, and rabbits (An et al., 1993; Honda et al., 1993; Bastien et al., 1994; Sando et al., 1994; Breyer et al., 1996b). Anatomically, the lung is composed of the bronchial tree, the alveoli, and a dense vascular network, including a variety of cell types. EP4 is highly expressed in airway smooth muscle cells, pulmonary fibroblasts, and smooth muscle cells of the pulmonary vein. In particular, together with the EP2 receptor, EP4 transcripts and proteins are abundantly expressed in human airway smooth muscle cells (Bradbury et al., 2005; Clarke et al., 2005; Mori et al., 2011; Benyahia et al., 2012). It is also known that EP4 activation causes potent relaxation in human and rat bronchial preparations (Lydford and McKechnie, 1994; Benyahia et al., 2012).

Pulmonary fibroblasts are important in the development and maintenance of lung structure and function. Their proliferation and phenotypic changes play critical roles in normal tissue repair as well as the development of pulmonary fibrosis (Ramos et al., 2001). The EP4 receptor is expressed in both fetal (Choung et al., 1998; Li et al., 2011) and adult lung fibroblasts (Huang et al., 2007; Nikam et al., 2011) in humans. Togo et al. (2008) demonstrated that the EP2 and EP4 receptors were expressed in normal pulmonary fibroblasts and that these receptors were increased in fibroblasts from patients with chronic obstructive pulmonary disease where they contribute to the pathogenesis of emphysema.

In the human pulmonary vasculature, the EP4 receptor is mostly expressed in the smooth muscle layer of the vein and only weakly in the artery (Walch et al., 1999; Foudi et al., 2008), suggesting that EP4 induces relaxation of the vein. This expression pattern

may change under disease conditions. Lai et al. (2008) reported that EP4 expression in the artery is readily detectable in pulmonary arterial hypertension in human and rat models. In other cell types in the lung, the EP4 receptor is found in human pulmonary microvascular endothelial cells (Aso et al., 2012), the human bronchial epithelial cell line BEAS-2B (N'Guesan et al., 2007), and human alveolar macrophages (Ratcliffe et al., 2007).

2. Function. EP4 may induce relaxation of the airway and inhibit smooth muscle cell proliferation. Buckley et al. (2011) reported that PGE₂-induced relaxation of the airway was mediated through EP4 in humans and rats. Mori et al. (2011) demonstrated that PGE₂ inhibited fetal bovine serum-induced proliferation of human airway smooth muscle cells via EP4 receptor activation. Taken together, these findings suggest that the EP4 receptor could potentially be a therapeutic target in treating pulmonary diseases such as asthma and chronic obstructive pulmonary disease. As they potentially occur downstream of EP4/cAMP signaling, both PKA and Epac are involved in anti-inflammatory (Oldenburger et al., 2012) and relaxation (Zieba et al., 2011) signaling in airway smooth muscle cells. It was also demonstrated that PGE₂ inhibits Platelet-derived growth factor-induced phenotype switching of tracheal smooth muscle cells, from a contractile to a proliferative phenotype, through the activation of the cAMP effectors PKA and Epac (Roscioni et al., 2011).

In fibroblasts, PGE₂ inhibits proliferation and collagen synthesis in human lungs (Huang et al., 2008). Proliferation and collagen synthesis were likewise attenuated by the activation of the cAMP effectors PKA and Epac, respectively. The accumulation of cAMP was promoted by EP4 receptor activation. In addition, chemotaxis of human lung fibroblasts was inhibited by EP4 (Li et al., 2011). Subtype-specific modulation of EP receptor activity could potentially be a new therapy for fibrotic lung disease.

An interesting vasodilatory effect of EP4-mediated signaling has been reported. Cyclic AMP accumulation in vascular smooth muscle cells is thought to be the main mechanism of prostanoid-induced vasorelaxation. Lai et al. (2008) demonstrated that iloprost, a stable analog of PGI₂, increased cAMP via the EP4 receptor in pulmonary arterial smooth muscle cells isolated from rats with pulmonary hypertension. Similarly, Foudi et al. (2008) reported that PGE₂-induced vasorelaxation of the human pulmonary vein was also mediated by the EP4 receptor. It has been demonstrated that IP receptors are downregulated in human pulmonary artery hypertension, whereas the EP4 receptor is stably expressed. The EP4 receptor could thus be a novel effective therapeutic target for the treatment of pulmonary artery hypertension.

I. Skin

1. *Expression.* Tober et al. (2007) reported that the EP4 receptor was abundant in epidermal keratinocytes, dermal leukocytes, and vascular endothelium in murine skin. UV-B exposure induced EP4 relocalization to the plasma membranes of keratinocytes, whereas its diffuse cytoplasmic staining pattern was unchanged in the rest of the epidermis. EP4 expression was also detected in sebocytes (Chen et al., 2009), hair follicles (Colombe et al., 2008), melanoma cells (Singh and Katiyar, 2011), and squamous cell carcinoma (Lee et al., 2005) in humans. Kabashima et al. (2003) reported the expression of EP4 receptor transcripts in Langerhans cells prepared from epidermis. Li et al. (2000) reported that EP4 receptor mRNA was upregulated in fetal rabbit skin wounds, yet downregulated in adult rabbit skin wounds.

2. *Function.* EP4 is involved in skin inflammation. It has been suggested that PGE₂ is upregulated within antigen-exposed skin (Ruzicka and Printz, 1982; Eberhard et al., 2002). Kabashima et al. (2003) demonstrated that PGE₂ promoted skin immune responses by enhancing the migration and maturation of Langerhans cells through EP4 signaling. Although the transcripts of all four PGE₂ receptor subtypes were detected in Langerhans cells, only EP4 deletion inhibited Langerhans cell accumulation in regional lymph nodes after application of fluorescein isothiocyanate to the skin. In addition, the immune responses in a dinitrofluorobenzene-induced contact hypersensitivity model were significantly attenuated in EP4 receptor KO mice and in EP4 antagonist-treated wild-type mice (Kabashima et al., 2007). Chun et al. (2007) suggested that PGE₂ exerted an antiapoptotic effect in UV-B-exposed mouse skin through EP4/PKA/Akt signaling. Thus, EP4 is suggested to promote immune response in skin, although the downstream signaling process of EP4 remains largely unknown.

J. Nervous System

1. *Expression.* Zhang and Rivest (1999) reported the distribution of EP4 receptor transcripts in the rat brain. The localization of the EP4 receptor was distinct from that of the EP2 receptor. EP4 receptors were mainly expressed in regions involved in the regulation of neuroendocrine and autonomic activities. Southall and Vasko (2001) demonstrated EP4 receptor expression in embryonic rat sensory neurons and adult rat dorsal root ganglia cells.

2. *Function.* Traditional NSAIDs exert their antinociceptive effects through the inhibition of prostaglandin. Accordingly, prostaglandin-mediated signaling has been thought to be involved in the development of inflammatory pain. Thermal and mechanical hyperalgesia, mechanical allodynia, and joint pain were suppressed by EP4 antagonists (Lin et al., 2006;

Kassuya et al., 2007; Nakao et al., 2007; Clark et al., 2008; Murase et al., 2008). Southall and Vasko (2001) demonstrated that EP4 receptors mediated the PGE₂-induced sensitization of sensory neurons. PGE₂-induced accumulation of cAMP and release of immunoreactive substance P and calcitonin gene-related peptide, all of which play important roles in the development of pain and hyperalgesia, were blocked by downregulation of EP4 receptors. Because the cAMP-PKA pathway is involved in the development of hyperalgesia after injury in the dorsal root ganglion (Song et al., 2006), EP4 may activate this pathway to regulate hyperalgesia.

Fever production may involve EP4 signaling. Oka et al. (2000) demonstrated that the EP4 receptor was expressed in regions that are involved in PGE₂-induced fever responses, including the organum vasculosum of the lamina terminalis and the adjacent preoptic area. Several reports have indicated that the EP4 receptor may contribute to PGE₂-induced changes in body temperature (Oka et al., 2000, 2003).

EP4 may also play a role in neuronal degeneration and regeneration. Hoshino et al. (2007) reported that PGE₂ enhanced the production of amyloid- β through the EP4 receptors in human neuroblastoma cells. Moreover, they observed that cognitive function of mice in an Alzheimer's disease model was improved by genetic and pharmacological inhibition of EP4 (Hoshino et al., 2012). In contrast, Liang et al. (2011) reported that an EP4 receptor agonist exerted a protective effect against cerebral ischemia injury in mice. Deletion of neuronal EP4 increased the severity of cerebral injury, as did endothelial deletion of EP4. The effect of EP4 on cerebral perfusion via endothelial nitric-oxide synthase function may be involved in such beneficial roles. A neuroprotective effect of EP4 signaling has been reported in various other models, e.g., a mouse multiple sclerosis model (Esaki et al., 2010), a rat spinal cord injury model (Umemura et al., 2010), and a mouse *N*-methyl-D-aspartate-mediated acute brain damage model (Ahmad et al., 2005). Taken together, these data suggest that EP4 contributes to hyperalgesia and fever production and plays protective roles in neuronal degeneration and regeneration, although its precise downstream signaling pathways have not been reported.

K. Other Systems

Prostanoids play a critical role in the regulation of platelet function. Several reports have indicated that EP4 mediates antithrombotic signaling (Iyu et al., 2010; Kuriyama et al., 2010; Philipose et al., 2010). Philipose et al. (2010) have reported that an EP4 agonist inhibited platelet aggregation, adhesion of platelets to fibrinogen, and thrombus formation *in vitro*. EP4 receptor activation could thus be a novel target for antithrombotic therapy. EP4 is also

expressed in the cochleae (Hori et al., 2009). Hori et al. (2009) reported that local EP4 agonist treatment improved noise-induced hearing loss in guinea pigs. Finally, Woodward et al. (2009) reported that an EP4 receptor agonist potently decreased intraocular pressure in laser-induced ocular hypertensive monkeys. EP4 could potentially be a new therapeutic target for antiglaucoma therapy.

IV. Conclusions

This article presents an overview of the functions of EP4 and its intracellular signaling pathways in physiologic and pathologic conditions. EP4 was originally identified as a G_s-coupled receptor and has been recognized to produce cAMP. Recent emerging evidence has revealed that, in addition to cAMP and its downstream signaling, EP4 also modulates a variety of signaling pathways, such as PI3K, β -arrestin, and transactivation of EGFR. The roles of these EP4-mediated pathways in physiologic and pathologic processes continue to be discovered.

Among the EP receptors, EP4 is reported to be most abundantly expressed in the heart, the ductus arteriosus, monocytes/macrophages, bone, and the colon. It maintains the physiologic functions of these organs through protein synthesis, a vasodilatory effect, regulation of immune response, anabolic effect, and mucosal barrier function, respectively. EP4 is also highly expressed in pathologic conditions, such as colorectal cancer, inflammatory bowel disease, rheumatoid arthritis, atherosclerotic plaque, and aortic aneurysm. Studies using mouse lines devoid of each of the four EP receptors further support the concept that EP4, but not the other EP receptors, plays a primary role in bone metabolism, osteoarthritis, and immune response in the skin. Therefore, the EP4 receptor appeared to be an attractive target by which to affect manifestations of various pathologic states by application of either agonists or antagonists of the receptor. In particular, EP4 agonists have drawn much attention for their promotion of osteogenesis and their suppression of colitis, and the potential usefulness of an EP4 agonist as a treatment of bone diseases or inflammatory bowel disease has been examined in clinical trials. EP4 antagonists may be suitable for use in the treatment of rheumatoid arthritis and osteoarthritis, where continuous dosing demands a drug with a superior safety profile. Traditional NSAIDs and COX inhibitors affect a number of other related prostaglandins and can cause serious side effects. The potential of an EP4 antagonist to improve prognosis in colon cancer, myocardial infarction, aortic aneurysm, neovascularization, and autoimmune encephalomyelitis is also of great interest.

Interestingly, modulating EP4 signaling could work on more than one mechanism, because EP4 is distributed

in various organs and circulating immune cells. For instance, inhibition of EP4 signaling has been expected to be useful as a treatment of migraine due to its cerebral vasoconstrictive and immunosuppressive effects. The possibilities for such dual mechanisms of action of EP4 signaling in pathologic conditions of various organs should be explored. In particular, it will be important to further clarify the intracellular signaling pathways and the precise molecular mechanisms involved in EP4-mediated pathophysiologic actions. These additional studies should lead to significant opportunities for new pharmacological therapies.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Yokoyama, Iwatsubo, Umemura, Fujita, Ishikawa.

References

- Ahmad AS, Ahmad M, de Brum-Fernandes AJ, and Doré S (2005) Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. *Brain Res* 1066:71–77.
- Aihara E, Nomura Y, Sasaki Y, Ise F, Kita K, and Takeuchi K (2007) Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. *Life Sci* 80:2446–2453.
- Akaogi J, Nozaki T, Satoh M, and Yamada H (2006) Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. *Endocr Metab Immune Disord Drug Targets* 6:383–394.
- Akaogi J, Yamada H, Kuroda Y, Nacionales DC, Reeves WH, and Satoh M (2004) Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. *J Leukoc Biol* 76:227–236.
- Akhter MP, Cullen DM, Gong G, and Recker RR (2001) Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. *Bone* 29:121–125.
- Akhter MP, Cullen DM, and Pan LC (2006) Bone biomechanical properties in EP4 knockout mice. *Calcif Tissue Int* 78:357–362.
- Alander CB and Raisz LG (2006) Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. *Prostaglandins Other Lipid Mediat* 81:178–183.
- Aldehni F, Tang T, Madsen K, Plattner M, Schreiber A, Friis UG, Hammond HK, Han PL, and Schweda F (2011) Stimulation of renin secretion by catecholamines is dependent on adenylyl cyclases 5 and 6. *Hypertension* 57:460–468.
- Altorki N (2004) COX-2: a target for prevention and treatment of esophageal cancer. *J Surg Res* 117:114–120.
- Alvarez-Soria MA, Largo R, Sanchez-Pernaute O, Calvo E, Egido J, and Herrero-Beaumont G (2007) Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. *Rheumatol Int* 27:911–917.
- An S, Yang J, Xia M, and Goetzl EJ (1993) Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. *Biochem Biophys Res Commun* 197:263–270.
- Aoi M, Aihara E, Nakashima M, and Takeuchi K (2004) Participation of prostaglandin E receptor EP4 subtype in duodenal bicarbonate secretion in rats. *Am J Physiol Gastrointest Liver Physiol* 287:G96–G103.
- Aoudjijt L, Potapov A, and Takano T (2006) Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor. *Am J Physiol Renal Physiol* 290:F1534–F1542.
- Arakawa T, Laneuville O, Miller CA, Lakkides KM, Wingerd BA, DeWitt DL, and Smith WL (1996) Prostanoid receptors of murine NIH 3T3 and RAW 264.7 cells. Structure and expression of the murine prostaglandin EP4 receptor gene. *J Biol Chem* 271:29569–29575.
- Aronoff DM, Canetti C, Serezani CH, Luo M, and Peters-Golden M (2005) Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. *J Immunol* 174:595–599.
- Aronoff DM, Hao Y, Chung J, Coleman N, Lewis C, Peres CM, Serezani CH, Chen GH, Flamand N, and Brock TG, et al. (2008) Misoprostol impairs female reproductive tract innate immunity against *Clostridium sordellii*. *J Immunol* 180:3222–3230.
- Arosh JA, Banu SK, Chapdelaine P, Emond V, Kim JJ, MacLaren LA, and Fortier MA (2003) Molecular cloning and characterization of bovine prostaglandin E2 receptors EP2 and EP4: expression and regulation in endometrium and myometrium during the estrous cycle and early pregnancy. *Endocrinology* 144:3076–3091.
- Arosh JA, Banu SK, Chapdelaine P, and Fortier MA (2004) Temporal and tissue-specific expression of prostaglandin receptors EP2, EP3, EP4, EP, and cyclooxygenases 1 and 2 in uterus and fetal membranes during bovine pregnancy. *Endocrinology* 145:407–417.
- Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, and Mutoh M, et al. (2002) Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. *Clin Cancer Res* 8:1157–1167.

- Aso H, Ito S, Mori A, Morioka M, Suganuma N, Kondo M, Imaizumi K, and Hasegawa Y (2012) Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells. *Am J Physiol Lung Cell Mol Physiol* 302:L266-L273.
- Astle S, Thornton S, and Slater DM (2005) Identification and localization of prostaglandin E2 receptors in upper and lower segment human myometrium during pregnancy. *Mol Hum Reprod* 11:279-287.
- Attur M, Al-Mussawir HE, Patel J, Kitay A, Dave M, Palmer G, Pillinger MH, and Abramson SB (2008) Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor. *J Immunol* 181:5082-5088.
- Babaev VR, Chew JD, Ding L, Davis S, Breyer MD, Breyer RM, Oates JA, Fazio S, and Linton MF (2008) Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. *Cell Metab* 8:492-501.
- Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A, and Arosh JA (2009) Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometrial cells through suppression of ERK1/2, AKT, NF-kappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. *Mol Endocrinol* 23:1291-1305.
- Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Heringers RM, and van de Velde CJ, et al. (2012) Use of aspirin postdiagnosis improves survival for colon cancer patients. *Br J Cancer* 106:1564-1570.
- Bastien L, Sawyer N, Grygorczyk R, Metters KM, and Adam M (1994) Cloning, functional expression, and characterization of the human prostaglandin E2 receptor EP2 subtype. *J Biol Chem* 269:11873-11877.
- Bátshake B, Nilsson C, and Sundelin J (1995) Molecular characterization of the mouse prostanoic EP1 receptor gene. *Eur J Biochem* 231:809-814.
- Baxter GS, Clayton JK, Coleman RA, Marshall K, Sangha R, and Senior J (1995) Characterization of the prostanoic receptors mediating constriction and relaxation of human isolated uterine artery. *Br J Pharmacol* 116:1692-1696.
- Bayston T, Ramesur S, Reize J, Jones KG, and Powell JT (2003) Prostaglandin E2 receptors in abdominal aortic aneurysms and human aortic smooth muscle cells. *J Vasc Surg* 38:354-359.
- Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. *Pharmacol Rev* 58:485-520.
- Benyahia C, Gomez I, Kanyinda L, Boukais K, Danel C, Leséche G, Longrois D, and Norel X (2012) PGE2 receptor (EP4) agonists: potent dilators of human bronchi and future asthma therapy? *Pulm Pharmacol Ther* 25:115-118.
- Berger HJ, Zaret BL, Speroff L, Cohen LS, and Wolfson S (1976) Regional cardiac prostaglandin release during myocardial ischemia in anesthetized dogs. *Circ Res* 38:566-571.
- Bergstrom S, Duner H, von EULER U, Pernow B, and Sjoval J (1959a) Observations on the effects of infusion of prostaglandin E in man. *Acta Physiol Scand* 45:145-151.
- Bergstrom S, Eliasson R, von EULER U, and Sjoval J (1959b) Some biological effects of two crystalline prostaglandin factors. *Acta Physiol Scand* 45:133-144.
- Bergstrom S and Sjoval J (1957) The isolation of prostaglandin. *Acta Chem Scand* 11:1086.
- Bhattacharya M, Asselin P, Hardy P, Guerguerian AM, Shichi H, Hou X, Varma DR, Bouayad A, Fouron JC, and Clyman RI, et al. (1999) Developmental changes in prostaglandin E2 receptor subtypes in porcine ductus arteriosus. Possible contribution in altered responsiveness to prostaglandin E2. *Circulation* 100:1751-1756.
- Birkenmeier K, Janke I, Schunck WH, Trimper K, Krieg T, Landsberger M, Völker U, Felix SB, and Staudt A (2008) Prostaglandin receptors mediate effects of substances released from ischemic rat hearts on non-ischaemic cardiomyocytes. *Eur J Clin Invest* 38:902-909.
- Blackwell KA, Raisz LG, and Pilbeam CC (2010) Prostaglandins in bone: bad cop, good cop? *Trends Endocrinol Metab* 21:294-301.
- Blesson CS, Büttner E, Mastroni B, and Sahlin L (2012) Prostaglandin receptors EP and FP are regulated by estradiol and progesterone in the uterus of ovariectomized rats. *Reprod Biol Endocrinol* 10:3.
- Boie Y, Sawyer N, Slipetz DM, Metters KM, and Abramovitz M (1995) Molecular cloning and characterization of the human prostanoic DP receptor. *J Biol Chem* 270:18910-18916.
- Boie Y, Stocco R, Sawyer N, Slipetz DM, Ungrin MD, Neuschäfer-Rube F, Püschel GP, Metters KM, and Abramovitz M (1997) Molecular cloning and characterization of the four rat prostaglandin E2 prostanoic receptor subtypes. *Eur J Pharmacol* 340:227-241.
- Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, McKenzie BS, Kastelein RA, Cua DJ, and de Waal Malefyt R (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. *J Exp Med* 206:535-548.
- Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. *Int J Impot Res* 8:47-52.
- Boring L, Gosling J, Cleary M, and Charo IF (1998) Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. *Nature* 394:894-897.
- Bouayad A, Bernier SG, Asselin P, Hardy P, Bhattacharya M, Quiniou C, Fouron JC, Guerguerian AM, Varma DR, and Clyman RI, et al. (2001a) Characterization of PGE2 receptors in fetal and newborn ductus arteriosus in the pig. *Semin Perinatol* 25:70-75.
- Bouayad A, Kajino H, Waleh N, Fouron JC, Andelfinger G, Varma DR, Skoll A, Vazquez A, Gobeil F Jr, and Clyman RI, et al. (2001b) Characterization of PGE2 receptors in fetal and newborn lamb ductus arteriosus. *Am J Physiol Heart Circ Physiol* 280:H2342-H2349.
- Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, and Knox A (2005) Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoic EP2/EP4 receptors and SP-1 transcription factor binding sites. *J Biol Chem* 280:29993-30000.
- Breyer MD and Breyer RM (2001) G protein-coupled prostanoic receptors and the kidney. *Annu Rev Physiol* 63:579-605.
- Breyer MD, Davis L, Jacobson HR, and Breyer RM (1996a) Differential localization of prostaglandin E2 receptor subtypes in human kidney. *Am J Physiol* 270:F912-F918.
- Breyer RM, Bagdassarian CK, Myers SA, and Breyer MD (2001) Prostaglandin receptors: subtypes and signaling. *Annu Rev Pharmacol Toxicol* 41:661-690.
- Breyer RM, Davis LS, Nian C, Redha R, Stillman B, Jacobson HR, and Breyer MD (1996b) Cloning and expression of the rabbit prostaglandin EP4 receptor. *Am J Physiol* 270:F485-F493.
- Bruce JI, Yule DI, and Shuttleworth TJ (2002) Ca2+-dependent protein kinase—a modulation of the plasma membrane Ca2+-ATPase in parotid acinar cells. *J Biol Chem* 277:48172-48181.
- Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, and Taskén K (2006) The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. *J Immunol* 176:7361-7370.
- Buchanan FG, Gordon DL, Matta P, Shi Q, Matrisian LM, and DuBois RN (2006) Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc Natl Acad Sci USA* 103:1492-1497.
- Buckley J, Birrell MA, Maher SA, Nials AT, Clarke DL, and Belvisi MG (2011) EP4 receptor as a new target for bronchodilator therapy. *Thorax* 66:1029-1035.
- Bundred NJ and Barnes NL (2005) Potential use of COX-2-aromatase inhibitor combinations in breast cancer. *Br J Cancer* 93 (Suppl 1):S10-S15.
- Butcher RW and Baird CE (1968) Effects of prostaglandins on adenosine 3',5'-monophosphate levels in fat and other tissues. *J Biol Chem* 243:1713-1717.
- Calabresi L, Rossoni G, Gomasrasi M, Sisto F, Berti F, and Franceschini G (2003) High-density lipoprotein protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. *Circ Res* 92:330-337.
- Cao RY, St Amand T, Li X, Yoon SH, Wang CP, Song H, Maruyama T, Brown PM, Zelt DT, and Funk CD (2012) Prostaglandin receptor EP4 in abdominal aortic aneurysms. *Am J Pathol* 181:313-321.
- Castleberry TA, Lu B, Smock SL, and Owen TA (2001) Molecular cloning and functional characterization of the canine prostaglandin E2 receptor EP4 subtype. *Prostaglandins Other Lipid Mediat* 65:167-187.
- Cha YI, Kim SH, Sepich D, Buchanan FG, Solnica-Krezel L, and DuBois RN (2006) Cyclooxygenase-1-derived PGE2 promotes cell motility via the G-protein-coupled EP4 receptor during vertebrate gastrulation. *Genes Dev* 20:77-86.
- Chaloux B, Caron AZ, and Guillemette G (2007) Protein kinase A increases the binding affinity and the Ca2+ release activity of the inositol 1,4,5-trisphosphate receptor type 3 in RINm5F cells. *Biol Cell* 99:379-388.
- Chandramouli A, Mercado-Pimentel ME, Hutchinson A, Gibadulinová A, Olson ER, Dickinson S, Shañas R, Davenport J, Owens J, and Bhattacharyya AK, et al. (2010) The induction of S100p expression by the Prostaglandin E2 (PGE2)/EP4 receptor signaling pathway in colon cancer cells. *Cancer Biol Ther* 10:1056-1066.
- Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, and Hla T (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. *Proc Natl Acad Sci USA* 101:591-596.
- Chaudhari A, Gupta S, and Kirschenbaum MA (1990) Biochemical evidence for PG12 and PGE2 receptors in the rabbit renal preglomerular microvasculature. *Biochim Biophys Acta* 1053:156-161.
- Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, Williams AC, and Paraskeva C (2006) Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. *Cancer Res* 66:3106-3113.
- Chen BC, Liao CC, Hsu MJ, Liao YT, Lin CC, Sheu JR, and Lin CH (2006) Peptidoglycan-induced IL-6 production in RAW 264.7 macrophages is mediated by cyclooxygenase-2, PGE2/PGE4 receptors, protein kinase A, I kappa B kinase, and NF-kappa B. *J Immunol* 177:681-693.
- Chen JX, O'Mara PW, Poole SD, Brown N, Ehinger NJ, Slaughter JC, Paria BC, Aschner JL, and Reese J (2012) Isoprostanates as physiological mediators of transition to newborn life: novel mechanisms regulating patency of the term and pre-term ductus arteriosus. *Pediatr Res* 72:122-128.
- Chen Q, Muramoto K, Masaaki N, Ding Y, Yang H, Mackey M, Li W, Inoue Y, Ackermann K, and Shirota H, et al. (2010) A novel antagonist of the prostaglandin E2 (EP4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. *Br J Pharmacol* 160:292-310.
- Chen W, Tsai SJ, Wang CA, Tsai JC, and Zouboulis CC (2009) Human sebocytes express prostaglandin E2 receptors EP2 and EP4 but treatment with prostaglandin E2 does not affect testosterone production. *Br J Dermatol* 161:674-677.
- Chen Y and Hughes-Fulford M (2000) Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. *Br J Cancer* 82:2000-2006.
- Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuliet E, and Nelson MA (2007) The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. *Exp Cell Res* 313:2969-2979.
- Chien EK and Macgregor C (2003) Expression and regulation of the rat prostaglandin E2 receptor type 4 (EP4) in pregnant cervical tissue. *Am J Obstet Gynecol* 189:1501-1510.
- Choung J, Taylor L, Thomas K, Zhou X, Kagan H, Yang X, and Polgar P (1996) Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen alpha1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. *J Cell Biochem* 71:254-263.
- Chun KS, Akunda JK, and Langenbach R (2007) Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the prostaglandin E2 receptors, EP2 and EP4. *Cancer Res* 67:2015-2021.

- Cipollone F, Fazio ML, Iezzi A, Cuccurullo C, De Cesare D, Uchino S, Spigonardo F, Marchetti A, Buttitta F, and Paloscio L, et al. (2005) Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. *Arterioscler Thromb Vasc Biol* 25:1925-1931.
- Clark CA, Schwarz EM, Zhang X, Ziran NM, Drissi H, O'Keefe RJ, and Zusick MJ (2005) Differential regulation of EP receptor isoforms during chondrogenesis and chondrocyte maturation. *Biochem Biophys Res Commun* 328:764-776.
- Clark P, Rowland SE, Denis D, Mathieu MC, Stocco R, Poirier H, Burch J, Han Y, Audoly L, and Therien AG, et al. (2008) MF498 [N-(4-(3,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl)sulfonyl-2-(2-methoxyphenyl)acetamide], a selective E prostanoicid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. *J Pharmacol Exp Ther* 325:425-434.
- Clarke DL, Belvisi MG, Smith SJ, Hardaker E, Yacoub MH, Meja KK, Newton R, Slater DM, and Giembycz MA (2005) Prostanoid receptor expression by human airway smooth muscle cells and regulation of the secretion of granulocyte colony-stimulating factor. *Am J Physiol Lung Cell Mol Physiol* 288:L238-L250.
- Clyman RI (2006) Mechanisms regulating the ductus arteriosus. *Biol Neonate* 89:330-335.
- Clyman RI, Mauray F, Roman C, and Rudolph AM (1978) PGE₂ is a more potent vasodilator of the lamb ductus arteriosus than is either PGI₂ or 6 keto PGF₁alpha. *Prostaglandins* 16:259-264.
- Cocconi F, Bodach E, White E, Bishai I, and Olley PM (1978) Prostaglandin I₂ is less relaxant than prostaglandin E₂ on the lamb ductus arteriosus. *Prostaglandins* 15:551-556.
- Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, and Sheldrick RL (1994a) A novel inhibitory prostanoid receptor in piglet saphenous vein. *Prostaglandins* 47:151-168.
- Coleman RA, Kennedy I, and Sheldrick RL (1987) New evidence with selective agonists and antagonists for the subclassification of PGE₂-sensitive (EP) receptors. *Adv Prostaglandin Thromboxane Leukot Res* 17A:467-470.
- Coleman RA, Smith WL, and Narumiya S (1994b) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev* 46:205-229.
- Colombe L, Michelet JF, and Bernard BA (2008) Prostanoid receptors in anagen human hair follicles. *Exp Dermatol* 17:63-72.
- Conti MA and Adelstein RS (1981) The relationship between calmodulin binding and phosphorylation of smooth muscle myosin kinase by the catalytic subunit of 3':5' cAMP-dependent protein kinase. *J Biol Chem* 256:3178-3181.
- Côté SC, Pasvanis S, Bounou S, and Dumais N (2009) CCR7-specific migration to CCL19 and CCL21 is induced by PGE₂ stimulation in human monocytes: Involvement of EP(2)/EP(4) receptors activation. *Mol Immunol* 46:2682-2693.
- Cruz Duarte P, St-Jacques B, and Ma W (2012) Prostaglandin E₂ contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neuron in ganglion explant cultures and in a neuropathic pain model. *Exp Neurol* 234:466-481.
- Dammenberg AJHL and Howe LR (2003) The role of COX-2 in breast and cervical cancer. *Prog Exp Tumor Res* 37:90-106.
- Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS, Tilford N, Sheldrick RL, Clark KL, and Coleman RA (2004) EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. *Br J Pharmacol* 141:580-585.
- de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, and Bos JL (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. *Nature* 396:474-477.
- DeWire SM, Ahn S, Leikowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. *Annu Rev Physiol* 69:483-510.
- Dey I and Chadee K (2008) Prostaglandin E₂ produced by Entamoeba histolytica binds to EP4 receptors and stimulates interleukin-8 production in human colonic cells. *Infect Immun* 76:5158-5163.
- Dey I, Giembycz MA, and Chadee K (2009) Prostaglandin E₂ couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines. *Br J Pharmacol* 156:475-485.
- Ding M, Kinoshita Y, Kishi K, Nakata H, Hassan S, Kawanami C, Sugimoto Y, Katsuyama M, Negishi M, and Narumiya S, et al. (1997) Distribution of prostaglandin E receptors in the rat gastrointestinal tract. *Prostaglandins* 53:199-216.
- Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, and Dubinett SM (2002) Autocrine/paracrine prostaglandin E₂ production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. *J Biol Chem* 277:50828-50833.
- Doherty GA, Byrne SM, Molloy ES, Malhotra V, Austin SC, Kay EW, Murray FE, and Fitzgerald DJ (2009) Proneoplastic effects of PGE₂ mediated by EP4 receptor in colorectal cancer. *BMC Cancer* 9:207.
- Duncan AM, Anderson LL, Funk CD, Abramovitz M, and Adam M (1995) Chromosomal localization of the human prostanoid receptor gene family. *Genomics* 25:740-742.
- Eberhard J, Jepsen S, Pohl L, Albers HK, and Agil Y (2002) Bacterial challenge stimulates formation of arachidonic acid metabolites by human keratinocytes and neutrophils in vitro. *Clin Diagn Lab Immunol* 9:132-137.
- Edwards RM (1985) Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. *Am J Physiol* 248:F779-F784.
- Esaki Y, Li Y, Sakata D, Yao C, Segi-Nishida E, Matsuoka T, Fukuda K, and Narumiya S (2010) Dual roles of PGE₂-EP4 signaling in mouse experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci USA* 107:12233-12238.
- Fang KM, Shu WH, Chang HC, Wang JJ, and Mak OT (2004) Study of prostaglandin receptors in mitochondria on apoptosis of human lung carcinoma cell line A549. *Biochem Soc Trans* 32:1078-1080.
- Fantidis P (2010) The role of intracellular 3':5'-cyclic adenosine monophosphate (cAMP) in atherosclerosis. *Curr Vasc Pharmacol* 8:464-472.
- Faour WH, He Y, He QW, de Ladurantaye M, Quintero M, Mancini A, and Di Battista JA (2001) Prostaglandin E₂ regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. *J Biol Chem* 276:31720-31731.
- Fedyk ER, Ripper JM, Brown DM, and Phipps RP (1996) A molecular analysis of PGE receptor (EP) expression on normal and transformed B lymphocytes: coexpression of EP1, EP2, EP3beta and EP4. *Mol Immunol* 33:33-45.
- Feldman AM (1993) Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. *Circulation* 87(5, Suppl)IV27-IV34.
- Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. *Gastroenterology* 115:182-205.
- Flanagan AM and Chambers TJ (1992) Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. *Endocrinology* 130:443-448.
- Foord SM, Marks B, Stoiz M, Bufflier E, Fraser NJ, and Lee MG (1996) The structure of the prostaglandin EP4 receptor gene and related pseudogenes. *Genomics* 35:182-188.
- Fortier I, Gallant MA, Hackett JA, Patry C, and de Brum-Fernandes AJ (2004) Immunolocalization of the prostaglandin E₂ receptor subtypes in human bone tissue: differences in foetal, adult normal, osteoporotic and pagetic bone. *Prostaglandins Leukot Essent Fatty Acids* 70:431-439.
- Foudi N, Kotelevets L, Louedec L, Lesèche G, Henin D, Chastre E, and Norel X (2008) Vasorelaxation induced by prostaglandin E₂ in human pulmonary vein: role of the EP4 receptor subtype. *Br J Pharmacol* 154:1631-1639.
- Frias MA, Rebsamen MC, Gerber-Wicht C, and Lang U (2007) Prostaglandin E₂ activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. *Cardiovasc Res* 73:57-65.
- Früs UG, Stubbe J, Uhrenholt TR, Svenningsen P, Nüsling RM, Skott O, and Jensen BL (2005) Prostaglandin E₂ EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. *Am J Physiol Renal Physiol* 289:F989-F997.
- Fujino H and Regan JW (2003) Prostanoid receptors and phosphatidylinositol 3-kinase: a pathway to cancer? *Trends Pharmacol Sci* 24:335-340.
- Fujino H and Regan JW (2006) EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. *Mol Pharmacol* 69:5-10.
- Fujino H, West KA, and Regan JW (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E₂. *J Biol Chem* 277:2614-2619.
- Fujino H, Xu W, and Regan JW (2003a) Prostaglandin E₂ induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. *J Biol Chem* 278:12151-12156.
- Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, and Fujiyama Y (2003b) Increased expression of interleukin 17 in inflammatory bowel disease. *Gut* 52:65-70.
- Fukuda EY, Lad SP, Mikolon DP, Iacobelli-Martínez M, and Li E (2005) Activation of lipid metabolism contributes to interleukin-8 production during Chlamydia trachomatis infection of cervical epithelial cells. *Infect Immun* 73:4017-4024.
- Fukuda Y, Sugimura M, Suzuki K, and Kanayama N (2007) Prostaglandin E₂ receptor EP4-selective antagonist inhibits lipopolysaccharide-induced cervical ripening in rabbits. *Acta Obstet Gynecol Scand* 86:1297-1302.
- Funk CD, Furci L, FitzGerald GA, Grygorczyk R, Rochette C, Bayne MA, Abramovitz M, Adam M, and Metters KM (1993) Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. *J Biol Chem* 268:26767-26772.
- Fushimi K, Nakashima S, You F, Takigawa M, and Shimizu K (2007) Prostaglandin E₂ downregulates TNF-alpha-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. *J Cell Biochem* 100:783-793.
- Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, and Mannon PJ (2006) Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. *Inflamm Bowel Dis* 12:9-15.
- Gagliardi MC, Teloni R, Mariotti S, Bromuro C, Chiani P, Romagnoli G, Giannini F, Torosantucci A, and Nisini R (2010) Endogenous PGE₂ promotes the induction of human Th17 responses by fungal beta-glucan. *J Leukoc Biol* 88:947-954.
- Gao MH, Tang T, Lai NC, Miyahara A, Guo T, Tang R, Firth AL, Yuan JX, and Hammond HK (2011) Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6 mutant. *Mol Pharmacol* 79:381-388.
- Gao Q, Zhan P, Alander CB, Kream BE, Hao C, Breyer MD, Pilbeam CC, and Raisz LG (2009) Effects of global or targeted deletion of the EP4 receptor on the response of osteoblasts to prostaglandin in vitro and on bone histomorphometry in aged mice. *Bone* 45:98-103.
- Genetos DC, Zhou Z, Li Z, and Donahue HJ (2012) Age-related changes in gap junctional intercellular communication in osteoblastic cells. *J Orthop Res* 30:1979-1984.
- Geng YJ, Ishikawa Y, Vatner DE, Wagner TE, Bishop SP, Vatner SF, and Homcy CJ (1999) Apoptosis of cardiac myocytes in Galpha transgenic mice. *Circ Res* 84:34-42.
- George RJ, Sturmoski MA, Anant S, and Houchen CW (2007) EP4 mediates PGE₂ dependent cell survival through the PI3 kinase/AKT pathway. *Prostaglandins Other Lipid Mediat* 83:112-120.
- Gilman AG (1970) A protein binding assay for adenosine 3':5'-cyclic monophosphate. *Proc Natl Acad Sci USA* 67:305-312.
- Gitlin JM, Trivedi DB, Langenbach R, and Loflin CD (2007) Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. *Cardiovasc Res* 73:227-236.
- Glerich M and Bos JL (2010) Epac: defining a new mechanism for cAMP action. *Annu Rev Pharmacol Toxicol* 50:355-375.
- Goldbatt MW (1993) A depressor substance in seminal fluid. *J Soc Chem Ind Lond* 52:1056-1057.
- Graeve L, Baumann M, and Heinrich PC (1993) Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense. *Clin Invest* 71:664-671.

- Graham S, Gamie Z, Polyzois I, Narvani AA, Tzafetta K, Tsiroidis E, Helioti M, Mantalaris A, and Tsiroidis E (2009) Prostaglandin EP2 and EP4 receptor agonists in bone formation and bone healing: In vivo and in vitro evidence. *Expert Opin Investig Drugs* 18:746-766.
- Gruzdev A, Nguyen M, Kovarova M, and Koller BH (2012) PGE2 through the EP4 receptor controls smooth muscle gene expression patterns in the ductus arteriosus critical for remodeling at birth. *Prostaglandins Other Lipid Mediat* 97:109-119.
- Gu G, Gao Q, Yuan X, Huang L, and Ge L (2012) Immunolocalization of adipocytes and prostaglandin E2 and its four receptor proteins EP1, EP2, EP3, and EP4 in the caprine cervix during spontaneous term labor. *Biol Reprod* 86:159-1-10.
- Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, and Rollins BJ (1998) Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. *Mol Cell* 2:275-281.
- Gurevich EV, Tesmer JJ, Mushagian A, and Gurevich VV (2012) G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. *Pharmacol Ther* 133:40-69.
- Ha CH, Kim JY, Zhao J, Wang W, Jhun BS, Wong C, and Jin ZG (2010) PKA phosphorylates histone deacetylase 5 and prevents its nuclear export, leading to the inhibition of gene transcription and cardiomyocyte hypertrophy. *Proc Natl Acad Sci USA* 107:15467-15472.
- Hackenthal E, Paul M, Ganten D, and Taugner R (1990) Morphology, physiology, and molecular biology of renin secretion. *Physiol Rev* 70:1067-1116.
- Hagino H, Kuraoka M, Kameyama Y, Okano T, and Teshima R (2005) Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. *Bone* 36:444-453.
- Hakeda Y, Yoshino T, Natakani Y, Kurihara N, Maeda N, and Kumegawa M (1986) Prostaglandin E2 stimulates DNA synthesis by a cyclic AMP-independent pathway in osteoblastic clone MC3T3-E1 cells. *J Cell Physiol* 128:155-161.
- Halls ML and Cooper DM (2011) Regulation by Ca²⁺-signaling pathways of adenylyl cyclases. *Cold Spring Harb Perspect Biol* 3:a004143.
- Harizi H, Juzan M, Pitard V, Moreau JF, and Gualde N (2002) Cyclooxygenase-2-induced prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. *J Immunol* 168:2255-2263.
- Hasumoto K, Sugimoto Y, Gotoh M, Segi E, Yamasaki A, Yamaguchi M, Honda H, Hirai H, Negishi M, and Kakizuka A, et al. (1997) Characterization of the mouse prostaglandin F receptor gene: a transgenic mouse study of a regulatory region that controls its expression in the stomach and kidney but not in the ovary. *Genes Cells* 2:571-580.
- Hatazawa R, Ohno R, Tanigami M, Tanaka A, and Takeuchi K (2006) Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. *J Pharmacol Exp Ther* 318:691-699.
- Hatazawa R, Tanaka A, Tanigami M, Amagase K, Kato S, Ashida Y, and Takeuchi K (2007) Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. *Am J Physiol Gastrointest Liver Physiol* 293:G788-G797.
- Hattori Y, Ohno T, Ae T, Saeki T, Arai K, Mizuguchi S, Saigenji K, and Majima M (2005) Gastric mucosal protection against ethanol by EP2 and EP4 signaling through the inhibition of leukotriene C4 production. *Am J Physiol Gastrointest Liver Physiol* 294:G80-G87.
- Hawcroft G, Ko CWS, and Hull MA (2007) Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. *Oncogene* 26:3006-3019.
- Hayashi M, Kita K, Ohashi Y, Aihara E, and Takeuchi K (2007) Phosphodiesterase isozymes involved in regulation of HCO₃⁻ secretion in isolated mouse duodenum in vitro. *Biochem Pharmacol* 74:1507-1513.
- Hazeki O, Okada T, Kurosu H, Takasuga S, Suzuki T, and Katada T (1998) Activation of PI 3-kinase by G protein $\beta\gamma$ subunits. *Life Sci* 62:1555-1559.
- He Q, Harding P, and LaPointe MC (2010) PKA, Rap1, ERK1/2, and p90RSK mediate PGE2 and EP4 signaling in neonatal ventricular myocytes. *Am J Physiol Heart Circ Physiol* 298:H136-H143.
- Hegen M, Sun L, Uozumi N, Kume K, Goad ME, Nickerson-Nutter CL, Shimizu T, and Clark JD (2003) Cytosolic phospholipase A2 α -deficient mice are resistant to collagen-induced arthritis. *J Exp Med* 197:1297-1302.
- Hikiji H, Takato T, Shimizu T, and Ishii S (2008) The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. *Prog Lipid Res* 47:107-126.
- Hinton AC, Grigsby PL, Pitzer BA, Brockman DE, Ittenbach RF, Hinton RB, and Myatt L (2010) Hormonal regulation of prostaglandin E2 receptors: localization and expression in rat cervical tissue. *Reprod Sci* 17:136-146.
- Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, and Narumiya S (1991) Cloning and expression of cDNA for a human thromboxane A2 receptor. *Nature* 349:617-620.
- Hirata M, Kakizuka A, Aizawa M, Ushikubi F, and Narumiya S (1994) Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. *Proc Natl Acad Sci USA* 91:11192-11196.
- Hishikari K, Suzuki J, Ogawa M, Isobe K, Takahashi T, Onishi M, Takayama K, and Isobe M (2009) Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. *Cardiovasc Res* 81:123-132.
- Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, and Yoshida N, et al. (1999) Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP2. *Proc Natl Acad Sci USA* 96:10501-10506.
- Ho D, Umemura M, Bravo C, and Iwatsubo K (2012) Recent advance in isoform-specific regulation of adenylyl cyclase. *Current Enzyme Inhibition* 8:170-182.
- Ho D, Yan L, Iwatsubo K, Vatner DE, and Vatner SF (2010) Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5. *Heart Fail Rev* 15:495-512.
- Ho SY and Anderson RH (1979) Anatomical closure of the ductus arteriosus: a study in 35 specimens. *J Anat* 128:829-836.
- Hombres DW, Meenan J, de Haas M, ten Kate FJ, von dem Borne AE, Tytgat GN, and van Deventer SJ (1996) Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. *Gut* 38:564-567.
- Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, Narumiya S, and Ichikawa A (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. *J Biol Chem* 268:7759-7762.
- Honda T, Segi-Nishida E, Miyachi Y, and Narumiya S (2006) Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. *J Exp Med* 203:325-335.
- Hori R, Nakagawa T, Sugimoto Y, Sakamoto T, Yamamoto N, Hamaguchi K, and Ito J (2009) Prostaglandin E receptor subtype EP4 agonist protects cochlea against noise-induced trauma. *Neuroscience* 160:813-819.
- Hoshino T, Nakaya T, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, and Mizushima T (2007) Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. *J Biol Chem* 282:32676-32688.
- Hoshino T, Namba T, Takehara M, Muroa N, Matsushima T, Sugimoto Y, Narumiya S, Suzuki T, and Mizushima T (2012) Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP4 receptor. *J Neurochem* 120:795-805.
- Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, and Mizushima T (2003) Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. *J Biol Chem* 278:12752-12758.
- Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, and Murphy KM (1993) Development of TH1 CD4⁺ T cells through IL-12 produced by Listeria-induced macrophages. *Science* 260:547-549.
- Huang S, Wetlaufer SH, Hogaboam C, Aronoff DM, and Peters-Golden M (2007) Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoind 2 receptor and cAMP signaling. *Am J Physiol Lung Cell Mol Physiol* 292:L405-L413.
- Huang SK, Wetlaufer SH, Chung J, and Peters-Golden M (2005) Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. *Am J Respir Cell Mol Biol* 39:482-489.
- Ikegami R, Sugimoto Y, Segi E, Katsuyama M, Karahashi H, Amano F, Maruyama T, Yamane H, Tsuchiya S, and Ichikawa A (2001) The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. *J Immunol* 166:4689-4696.
- Inoue H, Takamori M, Shimoyama Y, Ishibashi H, Yamamoto S, and Koshihara Y (2002) Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. *Br J Pharmacol* 136:287-295.
- Ishikawa Y, Iwatsubo K, Tsunematsu T, and Okumura S (2005) Genetic manipulation and functional analysis of cAMP signalling in cardiac muscle: implications for a new target of pharmacotherapy. *Biochem Soc Trans* 33:1337-1340.
- Ito M, Nakayama K, Konaka A, Sakata K, Ikeda K, and Maruyama T (2006) Effects of a prostaglandin EP4 agonist, ONO-4819, and risdroneate on trabecular microstructure and bone strength in mature ovariectomized rats. *Bone* 39:453-459.
- Iwamoto M, Osajima A, Tamura M, Suda T, Ota T, Kanegae K, Watanabe Y, Kabashima N, Anai H, and Nakashima Y (2003) Adrenomedullin inhibits pressure-induced mesangial MCP-1 expression through activation of protein kinase A. *J Nephrol* 16:673-681.
- Iwasaki K, Noguchi K, Endo H, Kondo H, and Ishikawa I (2003) Prostaglandin E2 downregulates interleukin-12 production through EP4 receptors in human monocytes stimulated with lipopolysaccharide from *Actinobacillus actinomycetemcomitans* and interferon-gamma. *Oral Microbiol Immunol* 18:150-155.
- Iwatsubo K, Okumura S, and Ishikawa Y (2006) Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. *Endocr Metab Immune Disord Drug Targets* 6:239-247.
- Iwatsubo K, Tsunematsu T, and Ishikawa Y (2003) Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. *Expert Opin Ther Targets* 7:441-451.
- Iyü D, Glenn JR, White AE, Johnson AJ, Fox SC, and Heptinstall S (2010) The role of prostanoind receptors in mediating the effects of PGE(2) on human platelet function. *Platelets* 21:329-342.
- Jager BV and Wollenman OJ (1942) An Anatomical Study of the Closure of the Ductus Arteriosus. *Am J Pathol* 18:595-613.
- Jain S, Chakraborty G, Raja R, Kale S, and Kundu GC (2008) Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. *Cancer Res* 68:7750-7759.
- Jiang MW, Yun SP, Park JH, Ryu JM, Lee JH, and Han HJ (2012) Cooperation of Epac1/Rap1/Akt and PKA in prostaglandin E2-induced proliferation of human umbilical cord blood derived mesenchymal stem cells: involvement of c-Myc and VEGF expression. *J Cell Physiol* 227:3756-3767.
- Jensen BL, Mann B, Skott O, and Kurtz A (1999) Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. *Kidney Int* 56:528-537.
- Jensen BL, Stubbe J, Hansen PB, Andreassen D, and Skott O (2001) Localization of prostaglandin E(2) EP2 and EP4 receptors in the rat kidney. *Am J Physiol Renal Physiol* 280:F1001-F1009.
- Jiang GL, Im WB, Donde Y, and Wheeler LA (2009) EP4 agonist alleviates indomethacin-induced gastric lesions and promotes chronic gastric ulcer healing. *World J Gastroenterol* 15:5149-5156.
- Jiang GL, Nieves A, Im WB, Old DW, Dinh DT, and Wheeler L (2007) The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. *J Pharmacol Exp Ther* 320:22-25.
- Jones RL and Chan K (2001) Distinction between relaxations induced via prostanoid EP (4) and IP(1) receptors in pig and rabbit blood vessels. *Br J Pharmacol* 134:313-324.
- Jovanović N, Pavlović M, Mirceviski V, Du Q, and Jovanović A (2006) An unexpected negative inotropic effect of prostaglandin F2alpha in the rat heart. *Prostaglandins Other Lipid Mediat* 80:110-119.

- Kabashima K, Nagamachi M, Honda T, Nishigori C, Miyachi Y, Tokura Y, and Narumiya S (2007) Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors. *Lab Invest* 87:49–55.
- Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, and Miyachi Y, et al. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. *J Clin Invest* 109:383–393.
- Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, and Narumiya S (2003) Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. *Nat Med* 9:744–749.
- Kaji H, Sugimoto T, Kanatani M, Fukase M, Kumegawa M, and Chihara K (1996) Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase. *J Bone Miner Res* 11: 62–71.
- Kajino H, Taniguchi T, Fujieda K, Ushikubi F, and Muramatsu I (2004) An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. *Pediatr Res* 56:586–590.
- Kakita A, Suzuki A, Ono Y, Miura Y, Itoh M, and Oiso Y (2004) Possible involvement of p38 MAP kinase in prostaglandin E1-induced ALP activity in osteoblast-like cells. *Prostaglandins Leukot Essent Fatty Acids* 70:469–474.
- Kamei D, Yamakawa K, Takegoshi Y, Mikami-Nakanishi M, Nakatani Y, Oh-Ishi S, Yasui H, Azuma Y, Hirasawa N, and Ohuchi K, et al. (2004) Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin synthetase-1. *J Biol Chem* 279:33684–33695.
- Kassuya CA, Ferreira J, Claudino RF, and Calixto JB (2007) Intraplantar PGE2 causes nociceptive behaviour and mechanical allodynia: the role of prostanoid E receptors and protein kinases. *Br J Pharmacol* 150:727–737.
- Katsushika S, Chen L, Kawabe J, Nilakantan R, Hainon NJ, Homcy CJ, and Ishikawa Y (1992) Cloning and characterization of a sixth adenylyl cyclase isoform: types V and VI constitute a subgroup within the mammalian adenylyl cyclase family. *Proc Natl Acad Sci USA* 89:8774–8778.
- Katsuyama M, Ikegami R, Karahashi H, Amano F, Sugimoto Y, and Ichikawa A (1998a) Characterization of the LPS-stimulated expression of EP2 and EP4 prostaglandin E receptors in mouse macrophage-like cell line, J774.1. *Biochem Biophys Res Commun* 251:727–731.
- Katsuyama M, Nishigaki N, Sugimoto Y, Morimoto K, Negishi M, Narumiya S, and Ichikawa A (1995) The mouse prostaglandin E receptor EP2 subtype: cloning, expression, and northern blot analysis. *FEBS Lett* 372:151–156.
- Katsuyama M, Sugimoto Y, Morimoto K, Hasumoto K, Fukumoto M, Negishi M, and Ichikawa A (1997) 'Distinct cellular localization' of the messenger ribonucleic acid for prostaglandin E receptor subtypes in the mouse uterus during pseudo-pregnancy. *Endocrinology* 138:344–350.
- Katsuyama M, Sugimoto Y, Okano K, Segi E, Ikegami R, Negishi M, and Ichikawa A (1998b) Characterization of the gene for the mouse prostaglandin E receptor subtype EP2: tissue-specific initiation of transcription in the macrophage and the uterus. *Biochem J* 330:1115–1121.
- Ke HZ, Crawford DT, Qi H, Simmons HA, Owen TA, Paralkar VM, Li M, Lu B, Grasser WA, and Cameron KO, et al. (2006) A nonprostanoid EP4 receptor selective prostaglandin E2 agonist restores bone mass and strength in aged, ovariectomized rats. *J Bone Miner Res* 21:565–575.
- Keates AC and Hanson PJ (1990) Regulation of mucus secretion by cells isolated from the rat gastric mucosa. *J Physiol* 423:397–409.
- Keila S, Keiner A, and Weinreb M (2001) Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro. *J Endocrinol* 168:131–139.
- Kelschenbach J, Ninkovic J, Wang J, Krishnan A, Charboneau R, Barke RA, and Roy S (2008) Morphine withdrawal inhibits IL-12 induction in a macrophage cell line through a mechanism that involves cAMP. *J Immunol* 180:3670–3679.
- Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, and Breyer RM (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. *Nat Med* 5: 217–220.
- Kennedy I, Coleman RA, Humphrey PP, Levy GP, and Lumley P (1982) Studies on the characterisation of prostanoid receptors: a proposed classification. *Prostaglandins* 24:667–689.
- Kessler CB and Delany AM (2007) Increased Notch 1 expression and attenuated stimulatory G protein coupling to adenylyl cyclase in osteonectin-null osteoblasts. *Endocrinology* 148:1666–1674.
- Khan KM, Howe LR, and Falcone DJ (2004) Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. *J Biol Chem* 279: 22039–22046.
- Khan KM, Kothari P, Du B, Dannenberg AJ, and Falcone DJ (2012) Matrix metalloproteinase-dependent microsomal prostaglandin synthase-1 expression in macrophages: role of TNF- α and the EP4 prostanoid receptor. *J Immunol* 188: 1970–1980.
- Kickler K, Maltby K, Ni Choileain S, Stephen J, Wright S, Hafler DA, Jabbour HN, and Astier AL (2012) Prostaglandin E2 affects T cell responses through modulation of CD46 expression. *J Immunol* 188:5303–5310.
- Kim C, Vigil D, Anand G, and Taylor SS (2006) Structure and dynamics of PKA signaling proteins. *Eur J Cell Biol* 85:651–654.
- Kim JI, Lakshminathan V, Frilot N, and Daaka Y (2010) Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalosome. *Mol Cancer Res* 8:569–577.
- Kim SH, Serezani CH, Okunishi K, Zaslon Z, Aronoff DM, and Peters-Golden M (2011) Distinct protein kinase A anchoring proteins direct prostaglandin E2 modulation of Toll-like receptor signaling in alveolar macrophages. *J Biol Chem* 286:8875–8883.
- King VL, Trivedi DB, Gitlin JM, and Loftin CD (2006) Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. *Arterioscler Thromb Vasc Biol* 26:1137–1143.
- Kisslov L, Hadad N, Rosengratan M, and Levy R (2012) HT-29 human colon cancer cell proliferation is regulated by cytosolic phospholipase A(2) α dependent PGE(2) via both PKA and PKB pathways. *Biochim Biophys Acta* 1821:1224–1234.
- Kitay Y, Barragan L, Qing H, Kondoh S, Jiang X, Johnson ML, and Bonewald LF (2010) Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the β -catenin and PKA pathways. *J Bone Miner Res* 25: 2657–2668.
- Kojima F, Kapoor M, Kawai S, Yang L, Aronoff DM, and Crofford LJ (2009) Prostaglandin E2 activates Rap1 via EP2/EP4 receptors and cAMP-signaling in rheumatoid synovial fibroblasts: involvement of Epa1 and PKA. *Prostaglandins Other Lipid Mediat* 89:26–33.
- Konya V, Philipose S, Bálint Z, Olschewski A, Marsche G, Sturm EM, Schicho R, Peskar BA, Schuligoi R, and Heinemann A (2011) Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors. *Eur J Immunol* 41: 2379–2389.
- Korn T, Bettelli E, Oukka M, and Kuchroo VK (2009) IL-17 and Th17 Cells. *Annu Rev Immunol* 27:485–517.
- Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, and Gillespie MT, et al. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. *J Clin Invest* 103:1345–1352.
- Krysan K, Reckamp KL, Sharma S, and Dubinett SM (2006) The potential and rationale for COX-2 inhibitors in lung cancer. *Anticancer Agents Med Chem* 6:209–220.
- Kubo S, Takahashi HK, Takei M, Iwagaki H, Yoshino T, Tanaka N, Mori S, and Nishibori M (2004) E-prostanoid (EP)2/EP4 receptor-dependent maturation of human monocyte-derived dendritic cells and induction of helper T2 polarization. *J Pharmacol Exp Ther* 309:1213–1220.
- Kunikata T, Araki H, Takeeda M, Kato S, and Takeuchi K (2001) Prostaglandin E receptor subtypes. *J Physiol Paris* 95:157–163.
- Kunikata T, Tanaka A, Miyazawa T, Kato S, and Takeuchi K (2002) 16,16-Dimethyl prostaglandin E2 inhibits indomethacin-induced small intestinal lesions through EP3 and EP4 receptors. *Dig Dis Sci* 47:894–904.
- Kuriyama S, Kashiwagi H, Yuhki K, Kojima F, Yamada T, Fujino T, Hara A, Takayama K, Maruyama T, and Yoshida A, et al. (2010) Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. *Thromb Haemostasis* 104:796–803.
- Kuroda E and Yamashita U (2003) Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. *J Immunol* 170:757–764.
- Kurzrok R and Lieb CC (1930) Biochemical studies on human semen. II. The action of semen on the human uterus. *Exp Biol Med* 28:268–272.
- Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, and Ono M (2004) Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. *FASEB J* 18:300–310.
- Kwok AH, Wang Y, Wang CY, and Leung FC (2008) Molecular cloning and characterization of chicken prostaglandin E receptor subtypes 2 and 4 (EP2 and EP4). *Gen Comp Evol* 157:99–106.
- la Sala A, He J, Laricchia-Robbio L, Gorini S, Iwasaki A, Braun M, Yap GS, Sher A, Ozato K, and Kelsall B (2009) Cholera toxin inhibits IL-12 production and CD8 α dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. *J Exp Med* 206:1227–1235.
- Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, Banat GA, Ghofrani HA, Seeger W, Grimminger F, and Schermuly RT (2008) Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. *Am J Respir Crit Care Med* 178:188–196.
- Lappano R and Maggiolini M (2011) G protein-coupled receptors: novel targets for drug discovery in cancer. *Nat Rev Drug Discov* 10:47–60.
- Leduc M, Breton B, Galés C, Le Guillou C, Bouvier M, Chemtob S, and Heveker N (2009) Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. *J Pharmacol Exp Ther* 331:297–307.
- Lee J, Banu SK, Nithy TK, Stanley JA, and Arosh JA (2012) Early pregnancy induced expression of prostaglandin E2 receptors EP2 and EP4 in the ovine endometrium and regulated by interferon tau through multiple cell signaling pathways. *Mol Cell Endocrinol* 348:211–223.
- Lee JL, Kim A, Kopelovich L, Bickers DR, and Athar M (2005) Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. *J Invest Dermatol* 125:818–825.
- Legler DF, Krause P, Scandella E, Singer E, and Groettrup M (2006) Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. *J Immunol* 176:966–973.
- Lejeune M, Leung P, Beck PL, and Chadee K (2010) Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity. *Am J Physiol Gastrointest Liver Physiol* 299: G1097–G1105.
- Lejeune M, Moreau F, and Chadee K (2011) Prostaglandin E2 produced by Entamoeba histolytica signals via EP4 receptor and alters claudin-4 to increase ion permeability of tight junctions. *Am J Pathol* 179:807–818.
- Lenz KM, Wright CL, Martin RC, and McCarthy MM (2011) Prostaglandin E $_2$ regulates AMPA receptor phosphorylation and promotes membrane insertion in preoptic area neurons and glia during sexual differentiation. *PLoS ONE* 6:e18500.
- Leonhardt A, Glaser A, Wegmann M, Schranz D, Seyberth H, and Nüssing R (2003) Expression of prostanoid receptors in human ductus arteriosus. *Br J Pharmacol* 138:655–659.
- Levi S, Goodlad RA, Lee CY, Stamp G, Walport MJ, Wright NA, and Hodgson HJ (1990) Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing. *Lancet* 336:840–843.
- Li HS, Hebda PA, Kelly LA, Ehrlich GD, Whitcomb DC, and Dohar JE (2000) Up-regulation of prostaglandin EP4 receptor messenger RNA in fetal rabbit skin wound. *Arch Otolaryngol Head Neck Surg* 126:1337–1343.